**PCT** WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :
A61K 37/12, A61F 2/02
C07K 13/00

A1

(11) International Publication Number: **WO 92/15323**

(43) International Publication Date: 17 September 1992 (17.09.92)

(21) International Application Number: PCT/US92/01968

(22) International Filing Date: 11 March 1992 (11.03.92)

(30) Priority data:
667,274 11 March 1991 (11.03.91) US

(71) Applicant: CREATIVE BIOMOLECULES, INC. [US/US]; 35 South Street, Hopkinton, MA 01748 (US).

(72) Inventors: COHEN, Charles, M. ; 98 Winthrop Street, Medway, MA 02053 (US). KUBERASAMPATH, Thangavel ; 6 Spring Street, Medway, MA 02053 (US). PANG, Roy, H., L. ; 16 Kimberly Drive, Medway, MA 02053 (US). OPPERMANN, Hermann ; 25 Summer Hill Road, Medway, MA 02053 (US). RUEGER, David, C. ; 19 Downey Street, Hopkinton, MA 01748 (US).

(74) Agent: PITCHER, Edmund, R.; Testa, Hurwitz & Thibeault, Exchange Place, 53 State Street, Boston, MA 02109-2809 (US).

(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), SE (European patent).

**Published**
*With international search report.*

(54) Title: PROTEIN-INDUCED MORPHOGENESIS

(57) Abstract

Disclosed are 1) amino acid sequence data, structural features, homologies and various other data characterizing morphogenic proteins, 2) methods of producing these proteins from natural and recombinant sources and from synthetic constructs, 3) morphogenic devices comprising these morphogenic proteins and a suitably modified tissue-specific matrix, and 4) methods of inducing non-chondrogenic tissue growth in a mammal.

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|---|---|---|---|---|---|
| AT | Austria | FI | Finland | ML | Mali |
| AU | Australia | FR | France | MN | Mongolia |
| BB | Barbados | GA | Gabon | MR | Mauritania |
| BE | Belgium | GB | United Kingdom | MW | Malawi |
| BF | Burkina Faso | GN | Guinea | NL | Netherlands |
| BG | Bulgaria | GR | Greece | NO | Norway |
| BJ | Benin | HU | Hungary | PL | Poland |
| BR | Brazil | IE | Ireland | RO | Romania |
| CA | Canada | IT | Italy | RU | Russian Federation |
| CF | Central African Republic | JP | Japan | SD | Sudan |
| CG | Congo | KP | Democratic People's Republic of Korea | SE | Sweden |
| CH | Switzerland | | | SN | Senegal |
| CI | Côte d'Ivoire | KR | Republic of Korea | SU | Soviet Union |
| CM | Cameroon | LI | Liechtenstein | TD | Chad |
| CS | Czechoslovakia | LK | Sri Lanka | TG | Togo |
| DE | Germany | LU | Luxembourg | US | United States of America |
| DK | Denmark | MC | Monaco | | |
| ES | Spain | MG | Madagascar | | |

# PROTEIN-INDUCED MORPHOGENESIS

## Background of the Invention

This invention relates to morphogenic proteins which can induce tissue morphogenesis in mammals; to methods of identifying these proteins and obtaining them from natural sources or producing synthetic forms of these proteins by expressing recombinant DNA encoding the proteins; to the fabrication of tissue-specific acellular matrices; and to methods for promoting tissue stasis, repair and regeneration, and methods for increasing progenitor cell populations using these proteins.

Cell differentiation is the central characteristic of morphogenesis which initiates in the embryo, and continues to various degrees throughout the life of an organism in adult tissue repair and regeneration mechanisms. The degree of morphogenesis in adult tissue varies among different tissues and is related, among other things, to the degree of cell turnover in a given tissue. On this basis, tissues can be divided into three broad categories: (1) tissues with static cell populations such as nerve and skeletal muscle where there is no cell division and most of the

cells formed during early development persist throughout adult life; (2) tissues containing conditionally renewing populations such as liver where there is generally little cell division but, in response to an appropriate stimulus, cells can divide to produce daughters of the same differentially defined type; and (3) tissues with permanently renewing populations including blood, testes and stratified squamous epithelia which are characterized by rapid and continuous cell turnover in the adult. Here, the terminally differentiated cells have a relatively short life span and are replaced through proliferation of a distinct subpopulation of cells, known as stem or progenitor cells.

The cellular and molecular events which govern the stimulus for differentiation of these cells is an area of intensive research. In the medical field, it is anticipated that the discovery of factor(s) which control cell differentiation and tissue morphogenesis will significantly advance medicine's ability to repair and regenerate diseased or damaged mammalian tissues and organs. Particularly useful areas include reconstructive surgery and in the treatment of tissue degenerative diseases including arthritis, emphysema, osteoporosis, cardiomyopathy, cirrhosis, and degenerative nerve diseases.

A number of different factors have been isolated in recent years which appear to play a role in cell differentiation. Some of these factors are gene transcription activators such as the NOTCH gene, identified in Drosophila and the related XOTCH gene identified in Xenopus, as well as a number of transcription activators identified in Caenorhabditis elegans.

Th hemopoietic system, because of its continually renewing cell population, is an area of concentrated study. Factors identifi d in this system which may be involv d in cell renewal include interleukin 3 (IL-3), erythropoietin, the CSFs (GM-CSF, G-CSF, M-CSF et al.) and various stem cell growth factors.

Other proteins thought to play a role in cell differentiation include proteins that are members of the family of insulin-like growth factors (IGF), members of the family of heparin-binding growth factors, (e.g., FGF - acidic and basic fibroblast growth factors, and ECDGF - embryonal carcinoma-derived growth factor) as well as several transforming oncogenes (hst and int-2, see for example, Heath et al., (1988), J. Cell Sci. Suppl. 10:256-256.) DIF (Differentiation Inducing Factor), identified in Dictyostelium discoideum, is another bioregulatory protein, directing prestock cell differentiation in that organism.

The structurally related proteins of the TGF-β superfamily of proteins also have been identified as involved in a variety of developmental events. For example, TGF-β and the polypeptides of the inhibin/activin group appear to play a role in the regulation of cell growth and differentiation. MIS (Mullerian Inhibiting Substance) causes regression of the Mullerian duct in development of the mammalian male embryo, and DPP, the gene product of the Drosophila decapentaplegic complex is required for appropriate dorsal-ventral specification. Similarly, Vg-1 is involved in mesoderm induction in Xenopus, and Vgr-1 has been identified in a variety of developing murine tissues.

Another sourc that has revealed a wealth of inf rmation is in the ar a of bone morphogenesis. The development and study of a bone model system has identified the developmental cascade of bone differentiation as consisting of chemotaxis of mesenchymal cells, proliferation of these progenitor cells, differentiation of these cells into chrondroblasts, cartilage calcification, vascular invasion, bone formation, remodeling, and finally, marrow differentiation (Reddi (1981) Collagen Rel. Res. 1:209-206). Proteins capable of inducing endochondral bone formation in a mammal when implanted in association with a matrix now have been identified in a number of different mammalian species, as have the genes encoding these proteins, (see, for example, U.S. Patent No. 4,968,590 and U.S. Patent No. 5,011,691, Ozkaynak, et al., (1990) EMBO J 9:2085-2093, and Ozkaynak et al., (1991) Biochem. Biophys. Res. Commn. 179:116-123 and USSN 07/841,646, filed February 21, 1992.) These proteins, which share significant amino acid sequence homology with one another as well as structural similarities with various members of the TGF-β super family of proteins, have been shown to induce endochondral bone formation and/or cartilage formation when implanted in a mammal in association with a suitably modified matrix. Proteins capable of inducing a similar developmental cascade of tissue morphogenesis of other tissues have not been identified.

It is an object of this invention to provide morphogenic proteins ("morphogens"), and methods for identifying these proteins, which are capable of inducing the developmental cascade of tissue

morphogen sis for a variety of tissues in mammals diff rent from bon or cartilage. This morphogenic activity includes the ability to induc proliferation and differentiation of progenitor cells, and the ability to support and maintain the differentiated phenotype through the progression of events that results in the formation of adult tissue. Another object is to provide genes encoding these proteins as well as methods for the expression and isolation of these proteins, from either natural sources or biosynthetic sources, using recombinant DNA techniques. Still another object is to provide tissue-specific acellular matrices that may be used in combination with these proteins, and methods for their production. Other objects include providing methods for increasing a progenitor cell population in a mammal, methods for stimulating progenitor cells to differentiate in vivo or in vitro and maintain their differentiated phenotype, methods for inducing tissue-specific growth in vivo and methods for the replacement of diseased or damaged tissue in vivo. These and other objects and features of the invention will be apparent from the description, drawings, and claims which follow.

## Summary of the Invention

This invention provides morphogenic proteins ("morphogens") capable of inducing the developmental cascade of tissue morphogenesis in a mammal. In particular, these proteins are capable of inducing the proliferation of uncommitted progenitor cells, and inducing the differentiation of these stimulated progenitor cells in a tissue-specific manner under appropriate environmental conditions. In addition, the morphogens are capable of supporting the growth and maintenance of these differentiated cells. These morphogenic activities allow the proteins of this invention to initiate and maintain the developmental cascade of tissue morphogenesis in an appropriate, morphogenically permissive environment, stimulating stem cells to proliferate and differentiate in a tissue-specific manner, and inducing the progression of events that culminate in new tissue formation. These morphogenic activities also allow the proteins to stimulate the "redifferentiation" of cells previously induced to stray from their differentiation path. Under appropriate environmental conditions it is anticipated that these morphogens also may stimulate the "dedifferentiation" of committed cells (see infra.)

In one aspect of the invention, the proteins and compositions of this invention are useful in the replacement of diseased or damaged tissue in a mammal, particularly when the damaged tissue interferes with normal tissue or organ function. Accordingly, it is anticipated that the proteins of this invention will be useful in the repair of damaged tissue such as, for example, damaged lung tissue resulting from emphysema, cirrhotic kidney or liver tissue, damaged heart or

blood vessel tissue, as may result from cardiomyopathies and/or ath rothrombotic or cardioemb lic strokes, damaged stomach tissue resulting from ulceric perf rations or their repair, damaged neural tissue as may result from physical injury, degenerative diseases such as Alzheimer's disease or multiple sclerosis or strokes, damaged dentin tissue as may result from disease or mechanical injury. When the proteins of this invention are provided to, or their expression stimulated at, a tissue-specific locus, the developmental cascade of tissue morphogenesis is induced (see infra). Cells stimulated ex vivo by contact with the proteins or agents capable of stimulating morphogen expression in these cells also may be provided to the tissue locus. In these cases the existing tissue provides the necessary matrix requirements, providing a suitable substratum for the proliferating and differentiating cells in a morphogenically permissive environment, as well as providing the necessary signals for directing the tissue-specificity of the developing tissue. Alternatively, the proteins or stimulated cells may be combined with a formulated matrix and implanted as a device at a locus in vivo. The formulated matrix should be a biocompatible, preferably biodegradable, appropriately modified tissue-specific acellular matrix having the characteristics described below.

In many instances, the loss of tissue function results from scar tissue, formed in response to an initial or repeated injury to the tissue. The degree of scar tissue formation generally depends on the regenerative properties of the injured tissue, and on the degree and type of injury. Thus, in another

aspect, the invention includes morphog ns that may be used to prevent or substantially inhibit th formation of scar tissue by providing the morphogens, or morphogen-stimulated cells, to a newly injured tissue loci (see infra).

The morphogens of this invention also may be used to increase or regenerate a progenitor or stem cell population in a mammal. For example, progenitor cells may be isolated from an individual's bone marrow, stimulated ex vivo for a time and at a morphogen concentration sufficient to induce the cells to proliferate, and returned to the bone marrow. Other sources of progenitor cells that may be suitable include biocompatible cells obtained from a cultured cell line, stimulated in culture, and subsequently provided to the body. Alternatively, the morphogen may be provided systemically, or implanted, injected or otherwise provided to a progenitor cell population in an individual to induce its mitogenic activity in vivo. For example, an agent capable of stimulating morphogen expression in the progenitor cell population of interest may be provided to the cells in vivo, for example systemically, to induce mitogenic activity. Similarly, a particular population of hemopoietic stem cells may be increased by the morphogens of this invention, for example by perfusing an individual's blood to extract the cells of interest, stimulating these cells ex vivo, and returning the stimulated cells to the blood. It is anticipated that the ability to augment an individual's progenitor cell population will significantly enhance existing methods for treating disorders resulting from a loss or reduction of a renewable cell population. Two particularly significant applications include the treatment of blood

disorders and impaired or lost immune functi n. Other cell p pulati ns whose proliferation may be exploited include th stem cells of th epidermis, which may be used in skin tissue regeneration, and the stem cells of the gastrointestinal lining, for example, in the healing of ulcers.

In still another aspect of the invention, the morphogens also may be used to support the growth and maintenance of differentiated cells, inducing existing differentiated cells to continue expressing their phenotype. It is anticipated that this activity will be particularly useful in the treatment of tissue disorders where loss of function is caused by cells becoming senescent or quiescent, such as may occur in osteoporosis. Application of the protein directly to the cells to be treated, or providing it by systemic injection, can be used to stimulate these cells to continue expressing their phenotype, thereby significantly reversing the effects of the dysfunction (see infra). Alternatively, administration of an agent capable of stimulating morphogen expression in vivo also may be used. In addition, the morphogens of this invention also may be used in gene therapy protocols to stimulate the growth of quiescent cells, thereby potentially enhancing the ability of these cells to incorporate exogenous DNA.

In yet another aspect of the invention, the morphogens of this invention also may be used to induce "redifferentiation" of cells that have strayed from their differentiation pathway, such as can occur during tumorgenesis. It is anticipated that this activity of the proteins will be particularly useful in treatments to reduce or substantially inhibit the growth of

neoplasms. The method also is anticipated to induce the de-and re-differentiation of these cells. As described supra, the proteins may be provided to the cells directly or systemically, or an agent capable of stimulating morphogen expression in vivo may be provided.

Finally, modulations of endogenous morphogen levels may be monitored as part of a method for detecting tissue dysfunction. Specifically, modulations in endogenous morphogen levels are anticipated to reflect changes in tissue or organ stasis. Tissue stasis may be monitored by detecting changes in the levels of the morphogen itself. For example, tissue samples may be obtained at intervals and the concentration of the morphogen present in the tissue detected by standard protein detection means known to those skilled in the art. As an example, a binding protein capable of interacting specifically with the morphogen of interest, such as an anti-morphogen antibody, may be used to detect the morphogen in a standard immunoassay. The morphogen levels detected then may be compared, the changes in the detected levels being indicative of the status of the tissue. Modulations in endogenous morphogen levels also may be monitored by detecting fluctuations in the body's natural antibody titer to morphogens (see infra.)

The morphogenic proteins and compositions of this invention can be isolated from a variety of naturally-occurring sources, or they may be constructed biosynthetically using conventional recombinant DNA technology. Similarly, the matrices may be derived from organ-specific tissue, or they may be formulated synthetically, as described below.

A key to these developments was the discov ry and characterization of naturally-occurring osteogenic proteins followed by observation of their remarkable properties. These proteins, originally isolated from bone, are capable of inducing the full developmental cascade of bone formation, including vascularization, mineralization, and bone marrow differentiation, when implanted in a mammalian body in association with a suitably modified matrix. Native proteins capable of inducing this developmental cascade, as well as DNA sequences encoding these proteins now have been isolated and characterized for a number of different species (e.g., human and mouse OP-1, OP-2, and CBMP-2. See, for example, U.S. Patent Nos. 4,968,590 and 5,011,691; U.S. Application Serial No. 841,646, filed February 21, 1992; Sampath et al. (1990) J. Bio. Chem 265:13198-13205; Ozkaynak, et al. (1990) EMBO J 9:2085-2 093 and Ozkaynak, et al. (1991) Biochem. Biophys. Res. Commn. 179:116-123.) The mature forms of these proteins share substantial amino acid sequence homology, especially in the C-terminal regions of the mature proteins. In particular, the proteins share a conserved six or seven cysteine skeleton in this region (e.g., the linear arrangement of these C-terminal cysteine residues is essentially conserved in the different proteins, in addition to other, apparently required amino acids (see Table II, infra)).

Polypeptide chains not normally associated with bone or bone formation, but sharing substantial amino acid sequence homology with the C-terminus of the osteogenic proteins, including the conserved six or seven cysteine skeleton, also have been identified as competent for inducing bone in mammals. Among these are amino acid sequences identified in Drosophila and

Xenopus, (e.g., DPP and Vgl; see, for example, U.S. Pat nt No. 5,011,691 and Table II, infra). In addition, non-native bi synthetic constructs designed based on extrapolation from these sequence homologies, including the conserved six or seven cysteine skeleton, have been shown to induce endochondral bone formation in mammals when implanted in association with an appropriate matrix (see U.S. Pat. No. 5,011,691 and Table III, infra).

It has now been discovered that this "family" of proteins sharing substantial amino acid sequence homology and the conserved six or seven cysteine skeleton are true morphogens, capable of inducing, in addition to bone and cartilage, tissue-specific morphogenesis for a variety of other organs and tissues. The proteins apparently bind to surface receptors or otherwise contact and interact with progenitor cells, predisposing or stimulating the cells to proliferate and differentiate in a morphogenically permissive environment. The morphogens are capable of inducing the developmental cascade of cellular and molecular events that culminate in the formation of new organ-specific tissue, including any vascularization, connective tissue formation, and nerve ennervation as required by the naturally occurring tissue.

It also has been discovered that the way in which the cells differentiate, whether, for example, they differentiate into bone-producing osteoblasts, hemopoietic cells, or liver cells, depends on the nature of their local environment (see infra). Thus, in addition to requiring a suitable substratum on which to anchor, the proliferating and differentiating cells also require appropriate signals to direct their

tissue-specificity. These signals may take the form of cell surface markers.

<

When the morphogens (or progenitor cells stimulated by these morphogens) are provided at a tissue-specific locus (e.g., by systemic injection or by implantation or injection at a tissue-specific locus, or by administration of an agent capable of stimulating morphogen expression in vivo), the existing tissue at that locus, whether diseased or damaged, has the capacity of acting as a suitable matrix. Alternatively, a formulated matrix may be externally provided together with the stimulated progenitor cells or morphogen, as may be necessary when the extent of injury sustained by the damaged tissue is large. The matrix should be a biocompatible, suitably modified acellular matrix having dimensions such that it allows the influx, differentiation, and proliferation of migratory progenitor cells, and is capable of providing a morphogenically permissive environment (see infra). The matrix preferably is tissue-specific, and biodegradable.

Formulated matrices may be generated from dehydrated organ-specific tissue, prepared for example, by treating the tissue with solvents to substantially remove the non-structural components from the tissue. Alternatively, the matrix may be formulated synthetically using a biocompatible, preferably in vivo

biodegradable, structural polymer such as collagen in association with suitable tissue-specific cell attachment factors. Currently preferred structural polymers comprise tissue-specific collagens. Currently preferred cell attachment factors include glycosaminoglycans and proteoglycans. The matrix further may be treated with an agent or agents to increase the number of pores and micropits on its surfaces, so as to enhance the influx, proliferation and differentiation of migratory progenitor cells from the body of the mammal.

Among the proteins useful in this invention are proteins originally identified as osteogenic proteins, such as the OP-1, OP-2 and CBMP2 proteins, as well as amino acid sequence-related proteins such as DPP (from Drosophila), Vgl (from Xenopus), Vgr-1 (from mouse, see Table II and Seq. ID Nos.5-14), and the recently identified GDF-1 protein (Seq. ID No. 14). The members of this family, which include members of the TGF-β super-family of proteins, share substantial amino acid sequence homology in their C-terminal regions. Table I, below, describes the various morphogens identified to date, including their nomenclature as used herein, and Seq. ID references.

TABLE I

| | |
|---|---|
| "OP-1" | Refers generically to the group of morphogenically active proteins expressed from part or all of a DNA sequence encoding OP-1 protein, including allelic and species variants thereof, e.g., human OP-1 ("hOP-1", Seq. ID No. 5, mature |

protein amino acid sequence), or m use OP-1 ("mOP-1", Seq. ID No. 6, mature protein amino acid sequence.) The c nserved seven cysteine skeleton is defined by residues 38 to 139 of Seq. ID Nos. 5 and 6. The cDNA sequences and the amino acids encoding the full length proteins are provided in Seq. Id Nos. 16 and 17 (hOP1) and Seq. ID Nos. 18 and 19 (mOP1.) The mature proteins are defined by residues 293-431 (hOP1) and 292-430 (mOP1). The "pro"regions of the proteins, cleaved to yield the mature, morphogenically active proteins are defined essentially by residues 30-292 (hOP1) and residues 30-291 (mOP1).

"OP-2" refers generically to the group of active proteins expressed from part or all of a DNA sequence encoding OP-2 protein, including allelic and species variants thereof, e.g., human OP-2 ("hOP-2", Seq. ID No. 7, mature protein amino acid sequence) or mouse OP-2 ("mOP-2", Seq. ID No. 8, mature protein amino acid sequence). The conserved seven cysteine skeleton is defined by residues 38 to 139 of Seq. ID Nos. 7 and 8. The cDNA sequences and the amino acids encoding the full length proteins are provided in Seq. Id Nos. 20 and 21 (hOP2) and Seq. ID Nos. 22 and 23 (mOP2.) The mature proteins are defined essentially by residues 264-402 (hOP2) and 261-399 (mOP2). The "pro" regions of the proteins, cleaved to yield

the mature, morphogenically activ proteins ar defined essentially by residues 18-263 (hOP2) and residues 18-260 (mOP1).

"CBMP2" refers generically to the morphogenically active proteins expressed from a DNA sequence encoding the CBMP2 proteins, including allelic and species variants thereof, e.g., human CBMP2A ("CBMP2A(fx)", Seq ID No. 9) or human CBMP2B DNA ("CBMP2B(fx)", Seq. ID No. 10).

"DPP(fx)" refers to protein sequences encoded by the Drosophila DPP gene and defining the conserved seven cysteine skeleton (seq. ID No. 11).

"Vgl(fx)" refers to protein sequences encoded by the Xenopus Vgl gene and defining the conserved seven cysteine skeleton (Seq. ID No. 12).

"Vgr-1(fx)" refers to protein sequences encoded by the murine Vgr-1 gene and defining the conserved seven cysteine skeleton (Seq. ID No. 13).

"GDF-1(fx)" refers to protein sequences encoded by the human GDF-1 gene and defining the conserved seven cysteine skeleton (seq. ID No. 14).

The OP-2 proteins have an additional cysteine residu in this region (e.g., see residue 41 of Seq. ID Nos. 7 and 8), in addition to the conserved cysteine skeleton in common with the other proteins in this family. The GDF-1 protein has a four amino acid insert within the conserved skeleton (residues 44-47 of Seq. ID No. 14) but this insert likely does not interfere with the relationship of the cysteines in the folded structure. In addition, the CBMP2 proteins are missing one amino acid residue within the cysteine skeleton.

The morphogens are inactive when reduced, but are active as oxidized homodimers and when oxidized in combination with other morphogens of this invention. Thus, as defined herein, a morphogen of this invention is a dimeric protein comprising a pair of polypeptide chains, wherein each polypeptide chain comprises at least the C-terminal six cysteine skeleton defined by residues 43-139 of Seq. ID No. 5, including functionally equivalent arrangements of these cysteines (e.g., amino acid insertions or deletions which alter the linear arrangement of the cysteines in the sequence but not their relationship in the folded structure), such that, when the polypeptide chains are folded, the dimeric protein species comprising the pair of polypeptide chains has the appropriate three-dimensional structure, including the appropriate intra- or inter-chain disulfide bonds such that the protein is capable of acting as a morphogen as defined herein. Specifically, the protein is capable of any of the following biological functions in a morphogenically permissive environment: stimulating proliferation of progenitor cells; stimulating the differentiation of progenitor cells; stimulating the proliferation of differentiated cells; and supporting the growth and maintenance of differentiated cells, including the

"r differentiation" of these cells. In additi n, it is also anticipated that the morphogens of this invention will be capable of inducing dedifferentiation of committed cells under appropriate environmental conditions.

In one preferred aspect, the morphogens of this invention comprise one of two species of generic amino acid sequences: Generic Sequence 1 (Seq. ID No. 1) or Generic Sequence 2 (Seq. ID No. 2); where each Xaa indicates one of the 20 naturally-occurring L-isomer, α-amino acids or a derivative thereof. Generic Sequence 1 comprises the conserved six cysteine skeleton and Generic Sequence 2 comprises the conserved six cysteine skeleton plus the additional cysteine identified in OP-2 (see residue 36, Seq. ID No. 2). In another preferred aspect, these sequences further comprise the following additional sequence at their N-terminus:

Cys Xaa Xaa Xaa Xaa (Seq. ID No. 15)
1 5

Preferred amino acid sequences within the foregoing generic sequences include: Generic Sequence 3 (Seq. ID No. 3) and Generic Sequence 4 (Seq. ID No. 4), listed below, which accommodate the homologies shared among the various preferred members of this morphogen family identified to date (see Table II), as well as the amino acid sequence variation among them. Generic Sequences 3 and 4 are composite amino acid sequences of the proteins presented in Table II and identified in Seq. ID Nos. 5-14. The generic sequences include both the amino acid identity shared by the sequences in Table II, as well as alternative residues

for the variabl positions within th sequence. Note that thes generic sequences all w for an additi nal cysteine at position 41 or 46 in Generic Sequences 3 or 4, respectively, providing an appropriate cysteine skeleton where inter- or intramolecular disulfide bonds can form, and contain certain critical amino acids which influence the tertiary structure of the proteins.

Generic Sequence 3

Leu Tyr Val Xaa Phe
1 5

Xaa Xaa Xaa Gly Trp Xaa Xaa Trp Xaa
10

Xaa Ala Pro Xaa Gly Xaa Xaa Ala
15 15 20

Xaa Tyr Cys Xaa Gly Xaa Cys Xaa
25 30

Xaa Pro Xaa Xaa Xaa Xaa Xaa
35

Xaa Xaa Xaa Asn His Ala Xaa Xaa
40 45

Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa
50

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
55 60

Cys Xaa Pro Xaa Xaa Xaa Xaa Xaa
65

Xaa Xaa Xaa Leu Xaa Xaa Xaa
70 75
Xaa Xaa Xaa Xaa Val Xaa Leu Xaa
80
Xaa Xaa Xaa Xaa Met Xaa Val Xaa
85 90
Xaa Cys Gly Cys Xaa
95

wherein each Xaa is independently selected from a group of one or more specified amino acids defined as follows: "Res." means "residue" and Xaa at res.4 = (Ser, Asp or Glu); Xaa at res.6 = (Arg, Gln, Ser or Lys); Xaa at res.7 = (Asp or Glu); Xaa at res.8 = (Leu or Val); Xaa at res.11 = (Gln, Leu, Asp, His or Asn); Xaa at res.12 = (Asp, Arg or Asn); Xaa at res.14 = (Ile or Val); Xaa at res.15 = (Ile or Val); Xaa at res.18 = (Glu, Gln, Leu, Lys, Pro or Arg); Xaa at res.20 = (Tyr or Phe); Xaa at res.21 = (Ala, Ser, Asp, Met, His, Leu or Gln); Xaa at res.23 = (Tyr, Asn or Phe); Xaa at res.26 = (Glu, His, Tyr, Asp or Gln); Xaa at res.28 = (Glu, Lys, Asp or Gln); Xaa at res.30 = (Ala, Ser, Pro or Gln); Xaa at res.31 = (Phe, Leu or Tyr); Xaa at res.33 = (Leu or Val); Xaa at res.34 = (Asn, Asp, Ala or Thr); Xaa at res.35 = (Ser, Asp, Glu, Leu or Ala); Xaa at res.36 = (Tyr, Cys, His, Ser or Ile); Xaa at res.37 = (Met, Phe, Gly or Leu); Xaa at res.38 = (Asn or Ser); Xaa at res.39 = (Ala, Ser or Gly); Xaa at res.40 = (Thr, Leu or Ser); Xaa at res.44 = (Ile or Val); Xaa at res.45 = (Val or Leu); Xaa at res.46 = (Gln or Arg); Xaa at res.47 = (Thr, Ala or Ser); Xaa at res.49 = (Val or Met); Xaa at res.50 = (His or Asn); Xaa at res.51 = (Phe, Leu, Asn, Ser, Ala or Val); Xaa

at res.52 = (Ile, Met, Asn, Ala or Val); Xaa at res.53 = (Asn, Lys, Ala or Glu); Xaa at res.54 = (Pro or Ser); Xaa at res.55 = (Glu, Asp, Asn, or Gly); Xaa at res.56 = (Thr, Ala, Val, Lys, Asp, Tyr, Ser or Ala); Xaa at res.57 = (Val, Ala or Ile); Xaa at res.58 = (Pro or Asp); Xaa at res.59 = (Lys or Leu); Xaa at res.60 = (Pro or Ala); Xaa at res.63 = (Ala or Val); Xaa at res.65 = (Thr or Ala); Xaa at res.66 = (Gln, Lys, Arg or Glu); Xaa at res.67 = (Leu, Met or Val); Xaa at res.68 = (Asn, Ser or Asp); Xaa at res.69 = (Ala, Pro or Ser); Xaa at res.70 = (Ile, Thr or Val); Xaa at res.71 = (Ser or Ala); Xaa at res.72 = (Val or Met); Xaa at res.74 = (Tyr or Phe); Xaa at res.75 = (Phe, Tyr or Leu); Xaa at res.76 = (Asp or Asn); Xaa at res.77 = (Asp, Glu, Asn or Ser); Xaa at res.78 = (Ser, Gln, Asn or Tyr); Xaa at res.79 = (Ser, Asn, Asp or Glu); Xaa at res.80 = (Asn, Thr or Lys); Xaa at res.82 = (Ile or Val); Xaa at res.84 = (Lys or Arg); Xaa at res.85 = (Lys, Asn, Gln or His); Xaa at res.86 = (Tyr or His); Xaa at res.87 = (Arg, Gln or Glu); Xaa at res.88 = (Asn, Glu or Asp); Xaa at res.90 = (Val, Thr or Ala); Xaa at res.92 = (Arg, Lys, Val, Asp or Glu); Xaa at res.93 = (Ala, Gly or Glu); and Xaa at res.97 = (His or Arg); and Generic Seq. 4:

Generic Sequence 4

Cys Xaa Xaa Xaa Xaa Leu Tyr Val Xaa Phe
1 5 10
Xaa Xaa Xaa Gly Trp Xaa Xaa Trp Xaa
15
Xaa Ala Pro Xaa Gly Xaa Xaa Ala
20 25
Xaa Tyr Cys Xaa Gly Xaa Cys Xaa
30 35

Xaa Pro Xaa Xaa Xaa Xaa Xaa
40
Xaa Xaa Xaa Asn His Ala Xaa Xaa
45 50
Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa
55
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
60 65
Cys Xaa Pro Xaa Xaa Xaa Xaa Xaa
70
Xaa Xaa Xaa Leu Xaa Xaa Xaa
75 80
Xaa Xaa Xaa Xaa Val Xaa Leu Xaa
85
Xaa Xaa Xaa Xaa Met Xaa Val Xaa
90 95
Xaa Cys Gly Cys Xaa
100

wherein each Xaa is independently selected from a group of one or more specified amino acids as defined by the following: "Res." means "residue" and Xaa at res.2 = (Lys or Arg); Xaa at res.3 = (Lys or Arg); Xaa at res.4 = (His or Arg); Xaa at res.5 = (Glu, Ser, His, Gly, Arg or Pro); Xaa at res.9 = (Ser, Asp or Glu); Xaa at res.11 = (Arg, Gln, Ser or Lys); Xaa at res.12 = (Asp or Glu); Xaa at res.13 = (Leu or Val); Xaa at res.16 = (Gln, Leu, Asp, His or Asn); Xaa at res.17 = (Asp, Arg, or Asn); Xaa at res.19 = (Ile or Val); Xaa at res.20 = (Ile or Val); Xaa at res.23 = (Glu, Gln, Leu, Lys, Pro or Arg); Xaa at res.25 = (Tyr or Phe); Xaa at res.26 = (Ala, Ser, Asp, Met, His, Leu, or Gln); Xaa at res.28 = (Tyr, Asn or Phe); Xaa at res.31 = (Glu, His, Tyr, Asp or Gln); Xaa at res.33 = Glu, Lys, Asp or Gln); Xaa at res.35 = (Ala, Ser or Pro); Xaa at res.36 = (Phe, Leu or Tyr); Xaa at res.38 = (Leu or Val); Xaa at res.39 =

(Asn, Asp, Ala or Thr); Xaa at res.40 = (Ser, Asp, Glu, Leu or Ala); Xaa at res.41 = (Tyr, Cys, His, Ser r Il ); Xaa at res.42 = (Met, Phe, Gly or Leu); Xaa at res.44 = (Ala, Ser or Gly); Xaa at res.45 = (Thr, Leu or Ser); Xaa at res.49 = (Ile or Val); Xaa at res.50 = (Val or Leu); Xaa at res.51 = (Gln or Arg); Xaa at res.52 = (Thr, Ala or Ser); Xaa at res.54 = (Val or Met); Xaa at res.55 = (His or Asn); Xaa at res.56 = (Phe, Leu, Asn, Ser, Ala or Val); Xaa at res.57 = (Ile, Met, Asn, Ala or Val); Xaa at res.58 = (Asn, Lys, Ala or Glu); Xaa at res.59 = (Pro or Ser); Xaa at res.60 = (Glu, Asp, or Gly); Xaa at res.61 = (Thr, Ala, Val, Lys, Asp, Tyr, Ser or Ala); Xaa at res.62 = (Val, Ala or Ile); Xaa at res.63 = (Pro or Asp); Xaa at res.64 = (Lys or Leu); Xaa at res.65 = (Pro or Ala); Xaa at res.68 = (Ala or Val); Xaa at res.70 = (Thr or Ala); Xaa at res.71 = (Gln, Lys, Arg or Glu); Xaa at res.72 = (Leu, Met or Val); Xaa at res.73 = (Asn, Ser or Asp); Xaa at res.74 = (Ala, Pro or Ser); Xaa at res.75 = (Ile, Thr or Val); Xaa at res.76 = (Ser or Ala); Xaa at res.77 = (Val or Met); Xaa at res.79 = (Tyr or Phe); Xaa at res.80 = (Phe, Tyr or Leu); Xaa at res.81 = (Asp or Asn); Xaa at res.82 = (Asp, Glu, Asn or Ser); Xaa at res.83 = (Ser, Gln, Asn or Tyr); Xaa at res.84 = (Ser, Asn, Asp or Glu); Xaa at res.85 = (Asn, Thr or Lys); Xaa at res.87 = (Ile or Val); Xaa at res.89 = (Lys or Arg); Xaa at res.90 = (Lys, Asn, Gln or His); Xaa at res.91 = (Tyr or His); Xaa at res.92 = (Arg, Gln or Glu); Xaa at res.93 = (Asn, Glu or Asp); Xaa at res.95 = (Val, Thr or Ala); Xaa at res.97 = (Arg, Lys, Val, Asp or Glu); Xaa at res.98 = (Ala, Gly or Glu); and Xaa at res.102 = (His or Arg).

Particularly useful sequences for use as morphogens in this invention include the C-terminal

domains, e.g., the C-terminal 96-102 amino acid r sidues f Vgl, Vgr-1, DPP, OP-1, OP-2, CBMP-2A, CBMP-2B and GDF-1 (see Table II, infra, and Seq. ID Nos. 5-14) which include at least the conserved six or seven cysteine skeleton. In addition, biosynthetic constructs designed from the generic sequences, such as COP-1, 3-5, 7, 16 (see Table III, infra) aso are useful. Other sequences include the C-terminal CBMP3 and the inhibins/activin proteins (see, for example, U.S. Pat. Nos. 4,968,590 and 5,011,691). Accordingly, other useful sequences are those sharing at least 70% amino acid sequence homology, and preferably 80% homology with any of the sequences above. These are anticipated to include allelic and species variants and mutants, and biosynthetic muteins, as well as novel members of this morphogenic family of proteins. Particularly envisioned in the family of related proteins are those proteins exhibiting morphogenic activity and wherein the amino acid changes from the preferred sequences include conservative changes, e.g., those as defined by Dayoff et al., Atlas of Protein Sequence and Structure; vol. 5, Suppl. 3, pp. 345-362, (M.O. Dayoff, ed., Nat'l BioMed. Research Fdn., Washington, D.C. 1979).

The currently most preferred protein sequences useful as morphogens in this invention include those having greater than 60% identity, preferably greater than 65% identity, with the amino acid sequence defining the conserved six cysteine skeleton of hOP1 (e.g., residues 43-139 of Seq. ID No. 5). These most preferred sequences include both allelic and species variants of the OP1 and OP2 proteins.

The invention thus provides proteins comprising any of the polypeptide chains described above, whether isolated from naturally-occurring sources, or produced by recombinant DNA techniques, and includes allelic and species variants of these proteins, naturally-occurring or biosynthetic mutants thereof, as well as various truncated and fusion constructs. Deletion or addition mutants also are envisioned to be active (see infra), including those which may alter the conserved C-terminal cysteine skeleton, provided that the alteration does not functionally disrupt the relationship of these cysteines in the folded structure. Accordingly, such active forms are considered the equivalent of the specifically described constructs disclosed herein. The proteins may include forms having varying glycosylation patterns, varying N-termini, a family of related proteins having regions of amino acid sequence homology, and active truncated or mutated forms of native or biosynthetic proteins, produced by expression of recombinant DNA in host cells.

The morphogenic proteins can be expressed from intact or truncated cDNA or from synthetic DNAs in procaryotic or eucaryotic host cells, and purified, cleaved, refolded, and dimerized to form morphogenically active compositions. Currently preferred host cells include E. coli or mammalian cells, such as CHO, COS or BSC cells.

Thus, in view of this disclosure, skilled genetic engineers can isolate genes from cDNA or genomic libraries of various different species which encode appropriate amino acid sequences, or construct DNAs from oligonucleotides, and then can express them

in various types of host cells, including both procaryotes and eucaryotes, to produce large quantities of active proteins capable of inducing tissue-specific cell differentiation and tissue morphogenesis in a variety of mammals including humans.

The invention thus further comprises these methods of inducing tissue-specific morphogenesis using the morphogenic proteins of this invention and pharmaceutical and therapeutic agents comprising the morphogens of this invention. The invention further comprises the use of these morphogens in the manufacture of pharmaceuticals for various medical procedures, including procedures for inducing tissue growth, procedures for inducing progenitor cell proliferation, procedures to inhibit neoplasm growth and procedures to promote phenotypic cell expression of differentiated cells.

## Brief Description of the Drawings

The foreg ing and other objects and features of this invention, as well as the invention itself, may be more fully understood from the following description, when read together with the accompanying drawings, in which:

FIGURE 1 is a photomicrograph of a Northern Blot identifying Vgr-1 specific transcripts in various adult murine tissues;

FIGURE 2 is a photomicrograph of a Northern Blot identifying mOP-1-specific mRNA expression in various murine tissues prepared from 2 week old mice (panel A) and 5 week old mice (Panel B);

FIGURE 3 is a photomicrograph of Northern Blots identifying mRNA expression of EF-Tu (A, control), mOP-1 (B, D), and Vgr-1 (C) in (1) 17-day embryos and (2) 3-day post natal mice;

FIGURE 4A and 4B are photomicrographs showing the presence of OP-1 (by immunofluorescence staining) in the cerebral cortex (A) and spinal cord (B);

FIGURE 5A and 5B are photomicrographs illustrating the ability of morphogen (OP-1) to induce undifferentiated NG108 calls (5A) to undergo differentiation of neural morphology (5B).

FIGURE 6A-6D are photomicrographs showing the effect of morphogen (OP-1) on human embryo carcinoma cell redifferentiation;

FIGURE 7 is a photomicrograph showing the effects of phosphate buffered saline (PBS, animal 1) r morphogen (OP-1, animal 2) on partially h patectomized rats;

FIGURE 8A - 8C are photomicrographs showing the effect of no treatment (8A), carrier matrix treatment (8B) and morphogen treatment (OP-1,8C) on dentin regeneration.

Detailed Description

Purification protocols first were d veloped which enabled isolation of the osteogenic (bone inductive) protein present in crude protein extracts from mammalian bone. (See PCT US 89/01453, and U.S. 4,968,590.) The development of the procedure, coupled with the availability of fresh calf bone, enabled isolation of substantially pure bovine osteogenic protein (BOP). BOP was characterized significantly; its ability to induce cartilage and ultimately endochondral bone growth in cat, rabbit, and rat were demonstrated and studied; it was shown to be able to induce the full developmental cascade of bone formation previously ascribed to unknown protein or proteins in heterogeneous bone extracts. This dose dependent and highly specific activity was present whether or not the protein was glycosylated (see U.S. Patent No. 4,968,958, filed 4/8/88 and Sampath et al., (1990) J. Biol. Chem. 265: pp. 13198-13205). Sequence data obtained from the bovine materials suggested probe designs which were used to isolate genes encoding osteogenic proteins from different species. Human and murine osteogenic protein counterparts have now been identified and characterized (see, for example, U.S. Pat. No. 5,011,691, Ozkaynak, et al., (1990) EMBO J 9:2085-2093, and Ozkaynak et al., (1991) Biochem. Biophys. Res. Commn. 179:116-123, and USSN 841,646, filed February 21, 1992, the disclosures of which are herein incorporated by reference.)

Sequence data from the bovine materials also suggested substantial homology with a number of proteins known in the art which were not known to play a role in bone formation. Bone formation assays

performed with these proteins showed that, when these proteins were implanted in a mammal in association with a suitable matrix, cartilag and endochondral bone formation was induced (see, for example, U.S. Patent No. 5,011,691.) One of these proteins is DPP, a Drosophila protein known to play a role in dorsal-ventral specification and required for the correct morphogenesis of the imaginal discs. Two other proteins are related sequences identified in Xenopus and mouse (Vgl and Vgr-1, respectively), thought to play a role in the control of growth and differentiation during embryogenesis. While DPP and Vgr-1 (or Vgr-1-like) transcripts have been identified in a variety of tissues (embryonic, neonatal and adult, Lyons et al., (1989) PNAS 86:4554-4 558, and see infra), Vgl transcripts, which are maternally inherited and spacially restricted to the vegetal endoderm, decline dramatically after gastrulation.

From these homologies a generic consensus sequence was derived which encompasses the active sequence required for inducing bone morphogenesis in a mammal when implanted in association with a matrix. The generic sequence has at least a conserved six cysteine skeleton (Generic Sequence 1, Seq. ID No. 1) or, optionally, a 7-cysteine skeleton (Generic Sequence 2, Seq. ID No. 2), which includes the conserved six cysteine skeleton defined by Generic Sequence 1, and an additional cysteine at residue 36, accomodating the additional cysteine residue identified in the OP2 proteins. Each "Xaa" in the generic sequences indicates that any one of the 20 naturally-occurring L-isomer, α-amino acids or a derivative

thereof may be used at that position. Longer generic sequences which also ar useful further comprise the following sequence at their N-termini:

Cys Xaa Xaa Xaa Xaa (Seq. ID No. 15)
1 5

Biosynthetic constructs designed from this generic consensus sequence also have been shown to induce cartilage and/or endochondral bone formation (e.g., COP-1, COP-3, COP-4, COP-5, COP-7 and COP-16, described in U.S. Patent No. 5,011,691 and presented below in Table III.) Table II, set forth below, compares the amino acid sequences of the active regions of native proteins that have been identified as morphogens, including human OP-1 (hOP-1, Seq. ID Nos. 5 and 16-17), mouse OP-1 (mOP-1, Seq. ID Nos. 6 and 18-19), human and mouse OP-2 (Seq. ID Nos. 7, 8, and 20-22), CBMP2A (Seq. ID No. 9), CBMP2B (Seq. ID No. 10), DPP (from Drosophila, Seq. ID No. 11), Vgl, (from Xenopus, Seq. ID No. 12), Vgr-1 (from mouse, Seq. ID No. 13), and GDF-1 (Seq. ID No. 14.) In the table, three dots indicates that the amino acid in that position is the same as the amino acid in hOP-1. Three dashes indicates that no amino acid is present in that position, and are included for purposes of illustrating homologies. For example, amino acid residue 60 of CBMP-2A and CBMP-2B is "missing". Of course, both these amino acid sequences in this region comprise Asn-Ser (residues 58, 59), with CBMP-2A then comprising Lys and Ile, whereas CBMP-2B comprises Ser and Ile.

TABLE II

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | hOP-1 | Cys | Lys | Lys | His | Glu | Leu | Tyr | Val |
| | mOP-1 | ... | ... | ... | ... | ... | ... | ... | ... |
| 5 | hOP-2 | ... | Arg | Arg | ... | ... | ... | ... | ... |
| | mOP-2 | ... | Arg | Arg | ... | ... | ... | ... | ... |
| | DPP | ... | Arg | Arg | ... | Ser | ... | ... | ... |
| | Vgl | ... | ... | Lys | Arg | His | ... | ... | ... |
| | Vgr-1 | ... | ... | ... | ... | Gly | ... | ... | ... |
| 10 | CBMP-2A | ... | ... | Arg | ... | Pro | ... | ... | ... |
| | CBMP-2B | ... | Arg | Arg | ... | Ser | ... | ... | ... |
| | GDF-1 | ... | Arg | Ala | Arg | Arg | ... | ... | ... |
| | | 1 | | | | 5 | | | |

15

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | hOP-1 | Ser | Phe | Arg | Asp | Leu | Gly | Trp | Gln | Asp |
| | mOP-1 | ... | ... | ... | ... | ... | ... | ... | ... | ... |
| | hOP-2 | ... | ... | Gln | ... | ... | ... | ... | Leu | ... |
| | mOP-2 | Ser | ... | ... | ... | ... | ... | ... | Leu | ... |
| 20 | DPP | Asp | ... | Ser | ... | Val | ... | ... | Asp | ... |
| | Vgl | Glu | ... | Lys | ... | Val | ... | ... | ... | Asn |
| | Vgr-1 | ... | ... | Gln | ... | Val | ... | ... | ... | ... |
| | CBMP-2A | Asp | ... | Ser | ... | Val | ... | ... | Asn | ... |
| | CBMP-2B | Asp | ... | Ser | ... | Val | ... | ... | Asn | ... |
| 25 | GDF-1 | ... | ... | ... | Glu | Val | ... | ... | His | Arg |
| | | | 10 | | | | | 15 | | |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | hOP-1 | Trp | Ile | Ile | Ala | Pro | Glu | Gly | Tyr | Ala |
| | mOP-1 | ... | ... | ... | ... | ... | ... | ... | ... | ... |
| 30 | hOP-2 | ... | Val | ... | ... | ... | Gln | ... | ... | Ser |
| | mOP-2 | ... | Val | ... | ... | ... | Gln | ... | ... | Ser |
| | DPP | ... | ... | Val | ... | ... | Leu | ... | ... | Asp |
| | Vgl | ... | Val | ... | ... | ... | Gln | ... | ... | Met |
| | Vgr-1 | ... | ... | ... | ... | ... | Lys | ... | ... | ... |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| CBMP-2A | ... | ... | Val | ... | ... | Pro | ... | ... | His |
| CBMP-2B | ... | ... | Val | ... | ... | Pro | ... | ... | Gln |
| GDF-1 | ... | Val | ... | ... | ... | Arg | ... | Phe | Leu |
| | | | 20 | | | | | 25 | |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| hOP-1 | Ala | Tyr | Tyr | Cys | Glu | Gly | Glu | Cys | Ala |
| mOP-1 | ... | ... | ... | ... | ... | ... | ... | ... | ... |
| hOP-2 | ... | ... | ... | ... | ... | ... | ... | ... | Ser |
| mOP-2 | ... | ... | ... | ... | ... | ... | ... | ... | ... |
| DPP | ... | ... | ... | ... | His | ... | Lys | ... | Pro |
| Vgl | ... | Asn | ... | ... | Tyr | ... | ... | ... | Pro |
| Vgr-1 | ... | Asn | ... | ... | Asp | ... | ... | ... | Ser |
| CBMP-2A | ... | Phe | ... | ... | His | ... | Glu | ... | Pro |
| CBMP-2B | ... | Phe | ... | ... | His | ... | Asp | ... | Pro |
| GDF-1 | ... | Asn | ... | ... | Gln | ... | Gln | ... | ... |
| | | | | 30 | | | | | 35 |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| hOP-1 | Phe | Pro | Leu | Asn | Ser | Tyr | Met | Asn | Ala |
| mOP-1 | ... | ... | ... | ... | ... | ... | ... | ... | ... |
| hOP-2 | ... | ... | ... | Asp | ... | Cys | ... | ... | ... |
| mOP-2 | ... | ... | ... | Asp | ... | Cys | ... | ... | ... |
| DPP | ... | ... | ... | Ala | Asp | His | Phe | ... | Ser |
| Vgl | Tyr | ... | ... | Thr | Glu | Ile | Leu | ... | Gly |
| Vgr-1 | ... | ... | ... | ... | Ala | His | ... | ... | ... |
| CBMP-2A | ... | ... | ... | Ala | Asp | His | Leu | ... | Ser |
| CBMP-2B | ... | ... | ... | Ala | Asp | His | Leu | ... | Ser |
| GDF-1 | Leu | ... | Val | Ala | Leu | Ser | Gly | Ser** | ... |
| | | | | | 40 | | | | |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| hOP-1 | Thr | Asn | His | Ala | Ile | Val | Gln | Thr | Leu |
| mOP-1 | ... | ... | ... | ... | ... | ... | ... | ... | ... |
| hOP-2 | ... | ... | ... | ... | ... | Leu | ... | Ser | ... |
| mOP-2 | ... | ... | ... | ... | ... | Leu | ... | Ser | ... |
| DPP | ... | ... | ... | ... | Val | ... | ... | ... | ... |

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | Vgl | Ser | ... | ... | ... | ... | Leu | ... | ... | ... |
| | Vgr-1 | ... | ... | ... | ... | ... | ... | ... | ... | ... |
| | CBMP-2A | ... | ... | ... | ... | ... | ... | ... | ... | ... |
| | CBMP-2B | ... | ... | ... | ... | ... | ... | ... | ... | ... |
| 5 | GDF-1 | Leu | ... | ... | ... | Val | Leu | Arg | Ala | ... |
| | | 45 | | | | | 50 | | | |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | hOP-1 | Val | His | Phe | Ile | Asn | Pro | Glu | Thr | Val |
| | mOP-1 | ... | ... | ... | ... | ... | ... | Asp | ... | ... |
| 10 | hOP-2 | ... | His | Leu | Met | Lys | ... | Asn | Ala | ... |
| | mOP-2 | ... | His | Leu | Met | Lys | ... | Asp | Val | ... |
| | DPP | ... | Asn | Asn | Asn | ... | ... | Gly | Lys | ... |
| | Vgl | ... | ... | Ser | ... | Glu | ... | ... | Asp | Ile |
| | Vgr-1 | ... | ... | Val | Met | ... | ... | ... | Tyr | ... |
| 15 | CBMP-2A | ... | Asn | Ser | Val | ... | Ser | --- | Lys | Ile |
| | CBMP-2B | ... | Asn | Ser | Val | ... | Ser | --- | Ser | Ile |
| | GDF-1 | Met | ... | Ala | Ala | Ala | ... | Gly | Ala | Ala |
| | | | 55 | | | | | 60 | | |

20

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | hOP-1 | Pro | Lys | Pro | Cys | Cys | Ala | Pro | Thr | Gln |
| | mOP-1 | ... | ... | ... | ... | ... | ... | ... | ... | ... |
| | hOP-2 | ... | ... | Ala | ... | ... | ... | ... | ... | Lys |
| | mOP-2 | ... | ... | Ala | ... | ... | ... | ... | ... | Lys |
| 25 | DPP | ... | ... | Ala | ... | ... | Val | ... | ... | ... |
| | Vgl | ... | Leu | ... | ... | ... | Val | ... | ... | Lys |
| | Vgr-1 | ... | ... | ... | ... | ... | ... | ... | ... | Lys |
| | CBMP-2A | ... | ... | Ala | ... | ... | Val | ... | ... | Glu |
| | CBMP-2B | ... | ... | Ala | ... | ... | Val | ... | ... | Glu |
| 30 | GDF-1 | Asp | Leu | ... | ... | ... | Val | ... | Ala | Arg |
| | | | | 65 | | | | | 70 | |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | hOP-1 | Leu | Asn | Ala | Ile | Ser | Val | Leu | Tyr | Phe |
| 35 | mOP-1 | ... | ... | ... | ... | ... | ... | ... | ... | ... |

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | hOP-2 | ... | Ser | ... | Thr | ... | ... | ... | ... | Tyr |
| | mOP-2 | ... | Ser | ... | Thr | ... | ... | ... | ... | Tyr |
| | Vgl | Met | Ser | Pro | ... | ... | Met | ... | Phe | Tyr |
| | Vgr-1 | Val | ... | ... | ... | ... | ... | ... | ... | ... |
| 5 | DPP | ... | Asp | Ser | Val | Ala | Met | ... | ... | Leu |
| | CBMP-2A | ... | Ser | ... | ... | ... | Met | ... | ... | Leu |
| | CBMP-2B | ... | Ser | ... | ... | ... | Met | ... | ... | Leu |
| | GDF-1 | ... | Ser | Pro | ... | ... | ... | ... | Phe | ... |
| | | | | | 75 | | | | | 80 |
| 10 | hOP-1 | Asp | Asp | Ser | Ser | Asn | Val | Ile | Leu | Lys |
| | mOP-1 | ... | ... | ... | ... | ... | ... | ... | ... | ... |
| | hOP-2 | ... | Ser | ... | Asn | ... | ... | ... | ... | Arg |
| | mOP-2 | ... | Ser | ... | Asn | ... | ... | ... | ... | Arg |
| | DPP | Asn | ... | Gln | ... | Thr | ... | Val | ... | ... |
| 15 | Vgl | ... | Asn | Asn | Asp | ... | ... | Val | ... | Arg |
| | Vgr-1 | ... | ... | Asn | ... | ... | ... | ... | ... | ... |
| | CBMP-2A | ... | Glu | Asn | Glu | Lys | ... | Val | ... | ... |
| | CBMP-2B | ... | Glu | Tyr | Asp | Lys | ... | Val | ... | ... |
| | GDF-1 | ... | Asn | ... | Asp | ... | ... | Val | ... | Arg |
| 20 | | | | | | 85 | | | | |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | hOP-1 | Lys | Tyr | Arg | Asn | Met | Val | Val | Arg |
| | mOP-1 | ... | ... | ... | ... | ... | ... | ... | ... |
| 25 | hOP-2 | ... | His | ... | ... | ... | ... | ... | Lys |
| | mOP-2 | ... | His | ... | ... | ... | ... | ... | Lys |
| | DPP | Asn | ... | Gln | Glu | ... | Thr | ... | Val |
| | Vgl | His | ... | Glu | ... | ... | Ala | ... | Asp |
| | Vgr-1 | ... | ... | ... | ... | ... | ... | ... | ... |
| 30 | CBMP-2A | Asn | ... | Gln | Asp | ... | ... | ... | Glu |
| | CBMP-2B | Asn | ... | Gln | Glu | ... | ... | ... | Glu |
| | GDF-1 | Gln | ... | Glu | Asp | ... | ... | ... | Asp |
| | | 90 | | | | | 95 | | |

35

| | | | | | | |
|---|---|---|---|---|---|---|
| | hOP-1 | Ala | Cys | Gly | Cys | His |
| | mOP-1 | ... | ... | ... | ... | ... |
| | hOP-2 | ... | ... | ... | ... | ... |
| | mOP-2 | ... | ... | ... | ... | ... |
| 5 | DPP | Gly | ... | ... | ... | Arg |
| | Vgl | Glu | ... | ... | ... | Arg |
| | Vgr-1 | ... | ... | ... | ... | ... |
| | CBMP-2A | Gly | ... | ... | ... | Arg |
| | CBMP-2B | Gly | ... | ... | ... | Arg |
| 10 | GDF-1 | Glu | ... | ... | ... | Arg |
| | | | | 100 | | |

**Between residues 43 and 44 of GDF-1 lies the amino acid sequence Gly-Gly-Pro-Pro.

15 Table III, set forth below, compares the amino acid sequence data for six related biosynthetic constructs designated COPs 1, 3, 4, 5, 7, and 16. These sequences also are presented in U.S. Pat. No. 5,011,691. As with Table II, the dots mean that in that 20 position there is an identical amino acid to that of COP-1, and dashes mean that the COP-1 amino acid is missing at that position.

25 TABLE III

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | COP-1 | Leu | Tyr | Val | Asp | Phe | Gln | Arg | Asp | Val |
| | COP-3 | ... | ... | ... | ... | ... | ... | ... | ... | ... |
| | COP-4 | ... | ... | ... | ... | ... | Ser | --- | ... | ... |
| 30 | COP-5 | ... | ... | ... | ... | ... | Ser | --- | ... | ... |
| | COP-7 | ... | ... | ... | ... | ... | Ser | --- | ... | ... |
| | COP-16 | ... | ... | ... | ... | ... | Ser | --- | ... | ... |
| | | 1 | | | | 5 | | | | |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| COP-1 | Gly | Trp | Asp | Asp | Trp | Ile | Ile | Ala |
| COP-3 | ... | ... | ... | ... | ... | ... | Val | ... |
| COP-4 | ... | ... | ... | ... | ... | ... | Val | ... |
| COP-5 | ... | ... | ... | ... | ... | ... | Val | ... |
| COP-7 | ... | ... | Asn | ... | ... | ... | Val | ... |
| COP-16 | ... | ... | Asn | ... | ... | ... | Val | ... |
| | 10 | | | | | 15 | | |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| COP-1 | Pro | Val | Asp | Phe | Asp | Ala | Tyr | Tyr |
| COP-3 | ... | Pro | Gly | Tyr | Gln | ... | Phe | ... |
| COP-4 | ... | Pro | Gly | Tyr | Gln | ... | Phe | ... |
| COP-5 | ... | Pro | Gly | Tyr | Gln | ... | Phe | ... |
| COP-7 | ... | Pro | Gly | Tyr | His | ... | Phe | ... |
| COP-16 | ... | Pro | Gly | Tyr | Gln | ... | Phe | ... |
| | | | 20 | | | | | 25 |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| COP-1 | Cys | Ser | Gly | Ala | Cys | Gln | Phe | Pro |
| COP-3 | ... | ... | ... | ... | ... | ... | ... | ... |
| COP-4 | ... | ... | ... | ... | ... | ... | ... | ... |
| COP-5 | ... | His | ... | Glu | ... | Pro | ... | ... |
| COP-7 | ... | His | ... | Glu | ... | Pro | ... | ... |
| COP-16 | ... | His | ... | Glu | ... | Pro | ... | ... |
| | | | | 30 | | | | |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| COP-1 | Ser | Ala | Asp | His | Phe | Asn | Ser | Thr |
| COP-3 | ... | ... | ... | ... | ... | ... | ... | ... |
| COP-4 | ... | ... | ... | ... | ... | ... | ... | ... |
| COP-5 | Leu | ... | ... | ... | ... | ... | ... | ... |
| COP-7 | Leu | ... | ... | ... | Leu | ... | ... | ... |
| COP-16 | Leu | ... | ... | ... | ... | ... | ... | ... |
| | | 35 | | | | | 40 | |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| COP-1 | Asn | His | Ala | Val | Val | Gln | Thr | Leu | Val |
| COP-3 | ... | ... | ... | ... | ... | ... | ... | ... | ... |
| COP-4 | ... | ... | ... | ... | ... | ... | ... | ... | ... |
| COP-5 | ... | ... | ... | ... | ... | ... | ... | ... | ... |
| COP-7 | ... | ... | ... | ... | ... | ... | ... | ... | ... |
| COP-16 | ... | ... | ... | ... | ... | ... | ... | ... | ... |
| | | | | 45 | | | | | 50 |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| COP-1 | Asn | Asn | Met | Asn | Pro | Gly | Lys | Val |
| COP-3 | ... | ... | ... | ... | ... | ... | ... | ... |
| COP-4 | ... | ... | ... | ... | ... | ... | ... | ... |
| COP-5 | ... | Ser | Val | ... | Ser | Lys | Ile | --- |
| COP-7 | ... | Ser | Val | ... | Ser | Lys | Ile | --- |
| COP-16 | ... | Ser | Val | ... | Ser | Lys | Ile | --- |
| | | | | | 55 | | | |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| COP-1 | Pro | Lys | Pro | Cys | Cys | Val | Pro | Thr |
| COP-3 | ... | ... | ... | ... | ... | ... | ... | ... |
| COP-4 | ... | ... | ... | ... | ... | ... | ... | ... |
| COP-5 | ... | ... | Ala | ... | ... | ... | ... | ... |
| COP-7 | ... | ... | Ala | ... | ... | ... | ... | ... |
| COP-16 | ... | ... | Ala | ... | ... | ... | ... | ... |
| | | 60 | | | | | 65 | |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| COP-1 | Glu | Leu | Ser | Ala | Ile | Ser | Met | Leu |
| COP-3 | ... | ... | ... | ... | ... | ... | ... | ... |
| COP-4 | ... | ... | ... | ... | ... | ... | ... | ... |
| COP-5 | ... | ... | ... | ... | ... | ... | ... | ... |
| COP-7 | ... | ... | ... | ... | ... | ... | ... | ... |
| COP-16 | ... | ... | ... | ... | ... | ... | ... | ... |
| | | | | 70 | | | | |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| COP-1 | Tyr | Leu | Asp | Glue | Asn | Ser | Thr | Val |
| COP-3 | ... | ... | ... | ... | ... | Glu | Lys | ... |
| COP-4 | ... | ... | ... | ... | ... | Glu | Lys | ... |
| COP-5 | ... | ... | ... | ... | ... | Glu | Lys | ... |
| COP-7 | ... | ... | ... | ... | ... | Glu | Lys | ... |
| COP-16 | ... | ... | ... | ... | ... | Glu | Lys | ... |
| | 75 | | | | | 80 | | |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| COP-1 | Val | Leu | Lys | Asn | Tyr | Gln | Glu | Met |
| COP-3 | ... | ... | ... | ... | ... | ... | ... | ... |
| COP-4 | ... | ... | ... | ... | ... | ... | ... | ... |
| COP-5 | ... | ... | ... | ... | ... | ... | ... | ... |
| COP-7 | ... | ... | ... | ... | ... | ... | ... | ... |
| COP-16 | ... | ... | ... | ... | ... | ... | ... | ... |
| | | | 85 | | | | | 90 |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| COP-1 | Thr | Val | Val | Gly | Cys | Gly | Cys | Arg |
| COP-3 | Val | ... | Glu | ... | ... | ... | ... | ... |
| COP-4 | Val | ... | Glu | ... | ... | ... | ... | ... |
| COP-5 | Val | ... | Glu | ... | ... | ... | ... | ... |
| COP-7 | Val | ... | Glu | ... | ... | ... | ... | ... |
| COP-16 | Val | ... | Glu | ... | ... | ... | ... | ... |
| | | | | | 95 | | | |

As is apparent from the foregoing amino acid sequence comparisons, significant amino acid changes can be made within the generic sequences while retaining the morphogenic activity. For example, while the GDF-1 protein sequence depicted in Table II shares only about 50% amino acid identity with the hOP1

sequence described therein, the GDF-1 sequence shares greater than 70% amino acid sequence homology with the hOP1 sequence, where homology is defined by allowed conservative amino acid changes within the sequence as defined by Dayoff, et al., Atlas of Protein Sequence and Structure vol.5, supp.3, pp.345-362, (M.O. Dayoff, ed., Nat'l BioMed. Res. Fd'n, Washington D.C. 1979.)

It now has been discovered that the family of proteins described by these sequences also is capable of initiating and maintaining the tissue-specific developmental cascade in tissues other than bone and cartilage. When combined with naive progenitor cells as disclosed herein, these proteins, termed morphogens, are capable of inducing the proliferation and differentiation of the progenitor cells. In the presence of appropriate tissue-specific signals to direct the differentiation of these cells, and a morphogenically permissive environment, these morphogens are capable of reproducing the cascade of cellular and molecular events that occur during embryonic development to yield functional tissue.

A key to these developments was the creation of a mammalian tissue model system, namely a model system for endochondral bone formation, and investigation of the cascade of events important for bone tissue morphogenesis. Work on this system has enabled discovery not only of bone inductive morphogens, but also of tissue inductive morphogens and their activities. The methods used to develop the bone model system, now well known in the art, along with the proteins of this invention, can be used to create model systems for other tissues, such as liver (see infra).

Using the model system for endochondral bone formation, it also has been discovered that the local environment in which the morphogenic material is placed is important for tissue morphogenesis. As used herein, "local environment" is understood to include the tissue structural matrix and the environment surrounding the tissue. For example, in addition to needing an appropriate anchoring substratum for their proliferation, the morphogen-stimulated cells need signals to direct the tissue-specificity of their differentiation. These signals vary for the different tissues and may include cell surface markers. In addition, vascularization of new tissue requires a local environment which supports vascularization. Using the bone model system as an example, it is known that, under standard assay conditions, implanting osteoinductive morphogens into loose mesenchyme in the absence of a tissue-specifying matrix generally does not result in endochondral bone formation unless very high concentrations of the protein are implanted. By contrast, implanting relatively low concentrations of the morphogen in association with a suitably modified bone-derived matrix results in the formation of fully functional endochondral bone (see, for example, Sampath et al. (1981) PNAS 78:7599-7 603 and U.S. Patent No. 4,975,526). In addition, a synthetic matrix comprised of a structural polymer such as tissue-specific collagen and tissue-specific cell attachment factors such as tissue-specific glycosylaminoglycans, will allow endochondral bone formation (see, for example, PCT publication US91/03603, published December 12, 1991 (WO 91/18558), incorporated herein by reference). Finally, if the morphogen and a suitable bone or cartilage-specific matrix (e.g., comprising Type I cartilage) are implanted together in loose mesenchyme, cartilage and endochondral bone formati n will result, including the formation of bone marrow and

a vascular system. Howev r, if the same composition is provided to a nonvascular environment, such as to cultured cells in vitro or at an cartilage-specific locus, tissue development does not continue beyond cartilage formation (see infra). Similarly, a morphogenic composition containing a cartilage-specific matrix composed of Type 2 collagen is expected to induce formation of non-cartilage tissue in vivo (e.g., hyaline). However, if the composition is provided to a vascular-supporting environment, such as loose mesenchyme, the composition is capable of inducing the differentiation of proliferating progenitor cells into chondrocytes and osteoblasts, resulting in bone formation.

It also has been discovered that tissue morphogenesis requires a morphogenically permissive environment. Clearly, in fully-functioning healthy tissue that is not composed of a permanently renewing cell population, there must exist signals to prevent continued tissue growth. Thus, it is postulated that there exists a control mechanism, such as a feedback control mechanism, which regulates the control of cell growth and differentiation. In fact, it is known that both TGF-β, and MIS are capable of inhibiting cell growth when present at appropriate concentrations. In addition, using the bone model system it can be shown that osteogenic devices comprising a bone-derived carrier (matrix) that has been demineralized and guanidine-extracted to substantially remove the noncollagenous proteins does allow endochondral bone formation when implanted in association with an

osteoinductive morphogen. If, however, the bone-derived carrier is not demineralized but rath r is washed only in low salt, for exampl , inducti n of endochondral bone formation is inhibited, suggesting the presence of one or more inhibiting factors within the carrier.

Another key to these developments was determination of the broad distribution of these morphogens in developing and adult tissue. For example, DPP is expressed in both embryonic and developing Drosophila tissue. Vgl has been identified in Xenopus embryonic tissue. Vgr-1 transcripts have been identified in a variety of murine tissues, including embryonic and developing brain, lung, liver, kidney and calvaria (dermal bone) tissue. Recently, Vgr-1 transcripts also have been identified in adult murine lung, kidney, heart, and brain tissue, with especially high abundance in the lung (see infra).

OP-1 and the CBMP2 proteins, both first identified as bone morphogens, have been identified in mouse and human placenta, hippocampus, calvaria and osteosarcoma tissue as determined by identification of OP-1 and CMBP2-specific sequences in cDNA libraries constructed from these tissues (see Ozkaynak, et al., (1990) EMBO J 9:2085-2093, and Ozkaynak et al., (1991) Biochem. Biophys. Res. Commn. 179:116-123). Additionally, the OP-1 protein is present in a variety of embryonic and developing tissues including kidney, liver, heart, adrenal tissue and brain as determined by Western blot analysis and immunolocalization (see infra). OP-1-specific transcripts also have been identified in both embryonic and developing tissues, most abundantly in developing kidney, bladder and brain

(s e infra). OP-1 also has been id ntified as a mesoderm inducing factor present during embryogenesis (see infra). Mor over, OP-1 has be n shown to b associated with in satellite muscle cells and associated with pluripotential stem cells in bone marrow following damage to adult murine endochondral bone, indicating its morphogenic role in tissue repair and regeneration. In addition, the recently identified protein GDF-1 (see Table II) has been identified in neural tissue (Lee, (1991) PNAS 88 4250-4254).

Exemplification

IDENTIFICATION AND ISOLATION OF MORPHOGENS

Among the proteins useful in this invention are proteins originally identified as bone inductive proteins, such as the OP-1, OP-2 and the CBMP proteins, as well as amino acid sequence-related proteins such as DPP (from Drosophila), Vgl (from Xenopus) and Vgr-1 (from mouse, see Table II and Sequence Listing). The members of this family, which include particular members of the TGF-β super family of structurally related proteins, share substantial amino acid sequence homology in their C-terminal regions. The OP-2 proteins have an extra cysteine residue in this region (position 41 of Seq. ID Nos. 7 and 8), in addition to the conserved cysteine skeleton in common with the other proteins in this family. The proteins are inactive when reduced, but are active as oxidized homodimeric species as well as when oxidized in combination with other morphogens.

Accordingly, the morphogens of this invention can be described by either of the following two species

of generic amino acid sequences: Generic Sequence 1 or Generic Sequence 2, (Seq. ID Nos. 1 and 2), where each Xaa indicates one of the 20 naturally-occurring L-isomer, α-amino acids r a derivative there f. Particularly useful sequences that fall within this family of proteins include the 96-102 C-terminal residues of Vgl, Vgr-1, DPP, OP-1, OP-2, CBMP-2A, CBMP-2B, and GDF-1, as well as their intact mature amino acid sequences. In addition, biosynthetic constructs designed from the generic sequences, such as COP-1, COP-3-5, COP-7, and COP-16 also are useful (see, for example, U.S. Pat. No. 5,011,691.)

Generic sequences showing preferred amino acids compiled from sequences identified to date and useful as morphogens (e.g., Tables II and III) are described by Generic Sequence 3 (Seq. ID No. 3) and Generic Sequence 4 (Seq. ID No. 4). Note that these generic sequences have a 7 or 8-cysteine skeleton where inter- or intramolecular disulfide bonds can form, and contain certain critical amino acids which influence the tertiary structure of the proteins. It is also contemplated that the differing N-termini of the naturally occurring proteins provide a tissue-specific or other, important modulating activity of these proteins.

Given the foregoing amino acid and DNA sequence information, the level of skill in the art, and the disclosures of U.S. Patent Nos. 4,968,590 and 5,011,691, PCT application US 89/01469, published October 19, 1989 (WO89/09788), and Ozkaynak, et al., (1990) EMBO J 9:2085-2093, and Ozkaynak et al., (1991) Biochem. Biophys. Res. Commn. 179:116-123 the disclosures of which are incorporated herein by reference, various DNAs can be constructed which encode

at least th active region of a morphogen of this invention, and various analogs thereof (including allelic variants and th se containing genetically engineered mutations), as well as fusion proteins, truncated forms of the mature proteins, deletion and insertion mutants, and similar constructs. Moreover, DNA hybridization probes can be constructed from fragments of the genes encoding any of these proteins, including seqeunces encoding the active regions or the pro regions of the proteins (see infra), or designed de novo from the generic sequence. These probes then can be used to screen different genomic and cDNA libraries to identify additional morphogenic proteins from different tissues.

The DNAs can be produced by those skilled in the art using well known DNA manipulation techniques involving genomic and cDNA isolation, construction of synthetic DNA from synthesized oligonucleotides, and cassette mutagenesis techniques. 15-100mer oligonucleotides may be synthesized on a Biosearch DNA Model 8600 Synthesizer, and purified by polyacrylamide gel electrophoresis (PAGE) in Tris-Borate-EDTA buffer. The DNA then may be electroeluted from the gel. Overlapping oligomers may be phosphorylated by T4 polynucleotide kinase and ligated into larger blocks which also may be purified by PAGE.

The DNA from appropriately identified clones then can be isolated, subcloned (preferably into an expression vector), and sequenced. Plasmids containing sequences of interest then can be transfected into an appropriate host cell for expression of the morphogen and further characterization. The host may be a

procary tic or eucaryotic cell since the former's inability to glycosylate protein will not destroy the protein's morphogenic activity. Useful host cells include E. c li, Saccharomyces, the insect/baculovirus cell system, myeloma cells, and various other mammalian cells. The vectors additionally may encode various sequences to promote correct expression of the recombinant protein, including transcription promoter and termination sequences, enhancer sequences, preferred ribosome binding site sequences, preferred mRNA leader sequences, preferred signal sequences for protein secretion, and the like.

The DNA sequence encoding the gene of interest also may be manipulated to remove potentially inhibiting sequences or to minimize unwanted secondary and tertiary structure formation. The recombinant morphogen also may be expressed as a fusion protein. After being translated, the protein may be purified from the cells themselves or recovered from the culture medium. All biologically active protein forms comprise dimeric species joined by disulfide bonds or otherwise associated, produced by refolding and oxidizing one or more of the various recombinant polypeptide chains within an appropriate eucaryotic cell or in vitro after expression of individual subunits. A detailed description of morphogens expressed from recombinant DNA in E. coli and in numerous different mammalian cells is disclosed in PCT publication US90/05903, published May 2, 1991 (WO91/05802) and U.S. Serial No. 841,646 filed February 21, 1992, the disclosures of which are hereby incorporated by reference.

Alternatively, morphogenic polypeptide chains can be synthesized chemically using conventional peptide synthesis techniques well known to those having

ordinary skill in th art. For example, the proteins may be synthesized intact or in parts n a Bi search solid phase peptide synthesizer, using standard operating procedures. Completed chains then are deprotected and purified by HPLC (high pressure liquid chromatography). If the protein is synthesized in parts, the parts may be peptide bonded using standard methodologies to form the intact protein. In general, the manner in which the morphogens are made can be conventional and does not form a part of this invention.

## MORPHOGEN DISTRIBUTION

The generic function of the morphogens of this invention throughout the life of the organism can be evidenced by their expression in a variety of disparate mammalian tissues. Determination of the tissue distribution of morphogens also may be used to identify different morphogens expressed in a given tissue, as well as to identify new, related morphogens. The proteins (or their mRNA transcripts) are readily identified in different tissues using standard methodologies and minor modifications thereof in tissues where expression may be low. For example, protein distribution may be determined using standard Western blot analysis or immunofluorescent techniques, and antibodies specific to the morphogen or morphogens of interest. Similarly, the distribution of morphogen transcripts may be determined using standard Northern hybridization protocols and transcript-specific probes.

Any probe capable of hybridizing specifically to a transcript, and distinguishing the transcript of interest from other, related transcripts may be used.

Because the morphogens of this invention share such high sequence homology in their active, C-terminal domains, the tissue distribution of a specific morphogen transcript may best be d termined using a probe specific for the pro region of the immature protein and/or the N-terminal region of the mature protein. Another useful sequence is the 3' non-coding region flanking and immediately following the stop codon. These portions of the sequence vary substantially among the morphogens of this invention, and accordingly, are specific for each protein. For example, a particularly useful Vgr-1-specific probe sequence is the PvuII-SacI fragment, a 265 bp fragment encoding both a portion of the untranslated pro region and the N-terminus of the mature sequence (see Lyons et al. (1989) PNAS 86:4554-4558 for a description of the cDNA sequence). Similarly, particularly useful mOP-1-specific probe sequences are the BstX1-BglI fragment, a 0.68 Kb sequence that covers approximately two-thirds of the mOP-1 pro region; a StuI-StuI fragment, a 0.2 Kb sequence immediately upstream of the 7-cysteine domain; and the Ear1-Pst1 fragment, an 0.3 Kb fragment containing a portion of the 3'untranslated sequence (See Seq. ID No. 18, where the pro region is defined essentially by residues 30-291.) Similar approaches may be used, for example, with hOP1 (Seq. ID No. 16) or human or mouse OP2 (Seq. ID Nos. 20 and 22.)

Using these morphogen-specific probes, which may be synthetically engineered or obtained from cloned sequences, morphogen transcripts can be identified in mammalian tissue, using standard methodologies well known to those having ordinary skill in the art. Briefly, total RNA is prepared from various adult murine tissues (e.g., liver, kidney, testis, heart,

brain, thymus and stomach) by a standard methodology such as by th method of Chomczyaski et al. ((1987) Anal. Biochem 162:156-159) and describ d below. Poly (A)+ RNA is prepared by using oligo (dT)-cellulose chromatography (e.g., Type 7, from Pharmacia LKB Biotechnology, Inc.). Poly (A)+ RNA (generally 15 μg) from each tissue is fractionated on a 1% agarose/formaldehyde gel and transferred onto a Nytran membrane (Schleicher & Schuell). Following the transfer, the membrane is baked at 80°C and the RNA is cross-linked under UV light (generally 30 seconds at 1 $mW/cm^2$). Prior to hybridization, the appropriate probe (e.g., the PvuII-SacI Vgr-1 fragment) is denatured by heating. The hybridization is carried out in a lucite cylinder rotating in a roller bottle apparatus at approximately 1 rev/min for approximately 15 hours at 37°C using a hybridization mix of 40% formamide, 5 x Denhardts, 5 x SSPE, and 0.1% SDS. Following hybridization, the non-specific counts are washed off the filters in 0.1 x SSPE, 0.1% SDS at 50°C. Northern blots performed using Vgr-1 probes specific to the variable N terminus of the mature sequence indicate that the Vgr-1 message is approximately 3.5 Kb.

Figure 1 is a photomicrograph representing a Northern blot analysis probing a number of adult murine tissues with the Vgr-1 specific probes: liver, kidney, testis, heart, brain, thymus and stomach, represented in lanes 3-10, respectively. Lanes 1 and 12 are size standards and lanes 2 and 11 are blank. Among the tissues tested, Vgr-1 appears to be expressed most abundantly in adult lung, and to a lesser extent in adult kidney, heart and brain. These results confirm and expand on earlier studies identifying Vgr-1 and Vgr-1-like transcripts in several embryonic and adult

murine tissue (Lyons et al. (1989) PNAS 86:4554-4558), as well as studies identifying OP-1 and CBMP2 in vari us human cDNA libraries (e.g., placenta, hipp campus, calvaria, and osteosarcoma, see Ozkaynak et al., (1990) EMBO 9:2085-2093).

Using the same general probing methodology, mOP-1 transcripts also have been identified in a variety of murine tissues, including embryo and various developing tissues, as can be seen in Figures 2 and 3. Details of the probing methodology are disclosed in Ozkaynak, et al., (1991) Biochem. Biophys. Res. Commn. 179:116-123, the disclosure of which is incorporated herein. The Northern blots represented in Figure 2 probed RNA prepared from developing brain, spleen, lung, kidney (and adrenal gland), heart, and liver in 13 day post natal mice (panel A) or 5 week old mice (panel B). The OP-1 specific probe was a probe containing the 3' untranslated sequences described supra (0.34 Kb EarI-Pst I fragment). As a control for RNA recovery, EF-Tu (translational elongation factor) mRNA expression also was measured (EF-Tu expression is assumed to be relatively uniform in most tissues).

The arrowheads indicate the OP1-specific messages observed in the various tissues. As can be seen in Fig. 2, OP-1 expression levels vary significantly in the spleen, lung, kidney and adrenal tissues, while the EF-Tu mRNA levels are constant. Uniformly lower levels of EF-Tu mRNA levels were found in the heart, brain and liver. As can be seen from the photomicrograph, the highest levels of OP-1 mRNA appear to be in kidney and adrenal tissue, followed by the brain. By contrast, heart and liver did not give a detectable signal. Not

shown are additional analyses performed on bladder tissue, which shows significant OP-1 mRNA expression, at levels close to those in kidney/adrenal tissue. The Northern blots also indicate that, like GDF-1, OP-1 mRNA expression may be bicistonic in different tissues. Four transcripts can be seen: 4 Kb, 2.4 Kb, 2.2 Kb, and 1.8 Kb transcripts can be identified in the different tissues, and cross probing with OP-1 specific probes from the proregion and N-terminal sequences of the gene indicate that these transcripts are OP-1 specific.

A side by side comparison of OP-1 and Vgr-1 in Figure 3 shows that the probes distinguish between the morphogens Vgr-1 and OP-1 transcripts in the different tissues, and also highlights the multiple transcription of OP-1 in different tissues. Specifically, Fig. 3 compares the expression of OP-1 (Panels B and D), Vgr-1 (Panel C) and EF-Tu (Panel A) (control) mRNA in 17 day embryos (lane 1) and 3 day post-natal mice (lane 2). The same filter was used for sequential hybridizations with labeled DNA probes specific for OP-1 (Panels B and D), Vgr-1 (Panel C), and EF-Tu (Panel A). Panel A: the EF-Tu specific probe (control) was the 0.4 Kb HindIII-SacI fragment (part of the protein coding region), the SacI site used belonged to the vector; Panel B: the OP-1 specific probe was the 0.68 Kb BstXI-BglI fragment containing pro region sequences; Panel D; the OP-1 specific probe was the 0.34 Kb EarI-PstI fragment containing the 3' untranslated sequence; Panel C: the Vgr-1 specific probe was the 0.26 Kb PvuII-SacI fragment used in the Vgr-1 blots described above.

The 1.8-2.5 Kb OP-1 mRNA appears approximately two times higher in thr day p st natal mice than in 17 day embryos, perhaps reflecting phases in bone and/or kidney d vel pment. In additi n, of the four messages found in brain, the 2.2 Kb transcript appears most abundant, whereas in lung and spleen the 1.8 Kb message predominates. Finally, careful separation of the renal and adrenal tissue in five week old mice reveals that the 2.2 Kb transcripts were derived from renal tissue and the 4 Kb mRNA is more prominent in adrenal tissue (see Figure 2).

Similarly, using the same general probing methodology, BMP3 and CBMP2B transcripts recently have been identified in abundance in lung tissue.

Morphogen distribution in embryonic tissue can be determined using five or six-day old mouse embryos and standard immunofluorescence techniques in concert with morphogen-specific antisera. For example, rabbit anti-OP-1 antisera is readily obtained using any of a number of standard antibody protocols well known to those having ordinary skill in the art. The antibodies then are fluorescently labelled using standard procedures. A five or six-day old mouse embryo then is thin-sectioned and the various developing tissues probed with the labelled antibody, again following standard protocols. Using this technique, OP-1 protein has been detected in developing brain and heart.

This method also may be used to identify morphogens in adult tissues undergoing repair. For example, a fracture site can be induced in a rat long bone such as the femur. The fracture then is allowed to heal for 2 or 3 days. The animal then is sacrificed

and the fractured sit sectioned and pr bed for th pr sence of the morphogen e.g., OP-1, with fluorescently labelled rabbit anti-OP-1 antisera using standard immunolocalization methodology. This technique identifies OP-1 in muscle satellite cells, the progenitor cells for the development of muscle, cartilage and endochondral bone. In addition, OP-1 is detected with potential pluripotential stem cells in the bone marrow, indicating its morphogenic role in tissue repair and regeneration.

OP-1 protein also has been identified in rat brain using standard immunofluorescence staining technique. Specifically, adult rat brain (2-3 months old) and spinal cord is frozen and sectioned. Anti-OP-1, raised in rabbits and purified on an OP-1 affinity column prepared using standard methodologies, was added to the sections under standard conditions for specific binding. Goat anti-rabbit IgG, labelled with fluorescence, then was used to visualize OP-1 antibody binding to tissue sections.

As can be seen in FIG 4A and 4B, immunofluorescence staining demonstrates the presence of OP-1 in adult rat central nervous system (CNS.) Similar and extensive staining is seen in both the brain (4A) and spinal cord (4B). OP-1 appears to be predominantly localized to the extracellular matrix of the grey matter, present in all areas except the neuronal cell bodies. In white matter, staining appears to be confined to astrocytes. A similar staining pattern also was seen in newborn rat (10 day old) brain sections.

## CELL DIFFERENTIATION

The ability of morphogens of this invention to induce cell differentiation can be determined by culturing early mesenchymal cells in the presence of the morphogen and then studying the histology of the cultured cells by staining with toluidine blue. For example, it is known that rat mesenchymal cells destined to become mandibular bone, when separated from the overlying epithelial cells at stage 11 and cultured in vitro under standard tissue culture conditions, will not continue to differentiate. However, if these same cells are left in contact with the overlying endoderm for an additional day, at which time they become stage 12 cells, they will continue to differentiate on their own in vitro to form chondrocytes. Further differentiation into obsteoblasts and, ultimately, mandibular bone, requires an appropriate local environment, e.g., a vascularized environment.

It has now been discovered that stage 11 mesenchymal cells, cultured in vitro in the presence of a morphogen, e.g., OP-1, continue to differentiate in vitro to form chondrocytes. These stage 11 cells also continue to differentiate in vitro if they are cultured with the cell products harvested from the overlying endodermal cells. Moreover, OP-1 can be identified in the medium conditioned by endodermal cells either by Western blot or immunofluorescence. This experiment may be performed with other morphogens and with different mesenchymal cells to assess the cell differentiation capability of different morphogens, as well as their distribution in different developing tissues.

As another example of morphogen-induced cell differentiation, the effect of OP-1 on the

differentiation of neuronal cells has been tested in culture. Specifically, th eff ct of OP-1 n the NG108-15 neuroblastoma x glioma hybrid clonal cell line has been assessed. The cell line shows a fibroblastic-type morphology in culture. The cell line can be induced to differentiate chemically using 0.5 mM butyrate, 1% DMSO or 500 mM Forskolin, inducing the expression of virtually all important neuronal properties of cultured primary neurons. However, chemical induction of these cells also induces cessation of cell division.

In the present experiment NG108-15 cells were subcultured on poly-L-lysine coated 6 well plates. Each well contained 40-50,000 cells in 2.5 ml of chemically defined medium. On the third day 2.5 $\mu$l of OP-1 in 60% ethanol containing 0.025% trifluoroacetic was added to each well. OP-1 concentrations of 0, 1, 10, 40 and 100 ng/ml were tested. The media was changed daily with new aliquots of OP-1. After four days with 40 and 100 ng OP-1/ml concentrations, OP-1 induced differentiation of the NG108-15 cells. Figure 5 shows the morphological changes that occur. The OP-1 induces clumping and rounding of the cells and the production of neurite outgrowths (processes). Compare FIG 5A (naive NG108-15 cells) with FIG 5B, showing the effects of OPI-treated cells. Thus the OP-1 can induce the cells to differentiate into a neuronal cell morphology. Some of the outgrowths appear to join in a synaptic-type junction. This effect was not seen in cells incubated with TGF-B1 at concentrations of 1 to 100 ng/ml.

The neuroprotective effects of OP-1 were demonstrated by comparison with chemical

differentiation agents on the NG108-15 cells. 50,000 cells were plated on 6 well plates and treated with butyrate, DMSO, Forskolin or OP-1 for four days. Cell counts demonstrated that in the cultures containing the chemical agents the differentiation was accompanied by a cessation of cell division. In contrast, the cells induced to differentiate by OP-1 continued to divide, as determined by $H^3$-thymidine uptake. The data suggest that OP-1 is capable of maintaining the stability of the cells in culture after differentiation.

As yet another, related example, the ability of the morphogens of this invention to induce the "redifferentiation" of transformed cells also has been assessed. Specifically, the effect of OP-1 on human EC cells (embryo carcinoma cells, NTERA-Z CL.D1) is disclosed herein. In the absence of an external stimulant these cells can be maintained as undifferentiated stem cells, and can be induced to grow in serum free media (SFM). In the absence of morphogen treatment the cells proliferate rampantly and are anchorage-independent. The effect of morphogen treatment is seen in Figs. 6A-D. Figs 6A and 6B show 4 days of growth in SFM in the presence of OP-1 (25ng/ml, 6A) or the absence of morphogen (6B). Figs. 6C and 6D are 5 days growth in the presence of 10ng/ml OP-1 (6C) or no morphogen (6D). Figs. 6C and 6D are at 10x and 20x magnification compared to FIGs 6A and 5B. As can readily be seen, in the presence of OP-1, EC cells grow as flattened cells, becoming anchorage dependent. In addition, growth rate is reduced approximately 10 fold. Finally, the cells are induced to differentiate.

## MAINTENANCE OF PHENOTYPE

The morphogens of this invention also may be used to maintain a cell's differentiated phenotype. This morphogenic capability is particularly useful for inducing the continued expression of phenotype in senescent or quiescent cells.

The phenotypic maintenance capability of morphogens is readily assessed. A number of differentiated cells become senescent or quiescent after multiple passages under standard tissue culture conditions in vitro. However, if these cells are cultivated in vitro in association with a morphogen of this invention, the cells are induced to maintain expression of their phenotype through multiple passages. For example, the alkaline phosphatase activity of cultured osteoblasts, like cultured osteoscarcoma cells and calvaria cells, is significantly reduced after multiple passages in vitro. However, if the cells are cultivated in the presence of a morphogen (e.g., OP-1), alkaline phosphatase activity is maintained over extended periods of time. Similarly, phenotypic expression of myocytes also is maintained in the presence of the morphogen. This experiment may be performed with other morphogens and different cells to assess the phenotypic maintenance capability of different morphogens on cells of differing origins.

Phenotypic maintenance capability also may be assessed in vivo, using a rat model for osteoporosis, disclosed in co-pending USSN 752,857, filed August 30, 1991,, incorporated herein by reference. As disclosed therein, Long Evans rats are ovariectomized to produce an osteoporotic condition resulting from decreased

estrogen production. Eight days after ovariectomy, rats are systemically provided with phosphate buffer d saline (PBS) or OP-1 (21 μg or 20 μg) for 22 days. The rats then are sacrificed and serum alkaline phosphatase levels, serum calcium levels, and serum osteocalcin levels are determined, using standard methodologies. Three-fold higher levels of osteocalcin levels are found in rats provided with 1 or 20 μg of OP-1. Increased alkaline phosphatase levels also were seen. Histomorphometric analysis on the tibial diaphysical bone shows OP-1 can reduce bone mass lost due to the drop in estrogen levels.

## CELL STIMULATION

The ability of the morphogens of this invention to stimulate the proliferation of progenitor cells also can be assayed readily in vitro. Useful naive stem cells include pluripotential stem cells, which may be isolated from bone marrow or umbilical cord blood using conventional methodologies, (see, for example, Faradji et al., (1988) Vox Sang. 55 (3):133-138 or Broxmeyer et al., (1989) PNAS 86 (10):3828-3832), as well as naive stem cells obtained from blood. Alternatively, embryonic cells (e.g., from a cultured mesodermal cell line) may be useful.

Another method for obtaining progenitor cells and for determining the ability of morphogens to stimulate cell proliferation is to capture progenitor cells from an in vivo source. For example, a biocompatible matrix material able to allow the influx of migratory progenitor cells may be implanted at an in vivo site long enough to allow the influx of migratory progenitor cells. For example, a bone-derived,

guanidine-extracted matrix, formulated as disclosed f r example in Sampath et al. ((1983) PNAS 80:6591-6595), or U.S. Patent No. 4,975,526, may be implanted into a rat at a subcutaneous site, essentially following the method of Sampath et al. (ibid). After three days the implant is removed, and the progenitor cells associated with the matrix dispersed and cultured.

Progenitor cells, however obtained, then are incubated in vitro with a suspected morphogen under standard cell culture conditions well known to those having ordinary skill in the art. In the absence of external stimuli, the progenitor cells do not, or minimally proliferate on their own in culture. However, if the cells are cultured in the presence of a morphogen, such as OP-1, they are stimulated to proliferate. Cell growth can be determined visually or spectrophotometrically using standard methods well known in the art.

## PROLIFERATION OF PROGENITOR CELL POPULATIONS

Progenitor cells may be stimulated to proliferate in vivo or ex vivo. The cells may be stimulated in vivo by injecting or otherwise providing a sterile preparation containing the morphogen into the individual. For example, the hemopoietic pluripotential stem cell population of an individual may be stimulated to proliferate by injecting or otherwise providing an appropriate concentration of the morphogen to the individual's bone marrow.

Progenitor cells may be stimulated ex vivo by contacting progenitor cells of the population to be enhanced with a morphogen under sterile conditions at a

concentration and for a time sufficient to stimulate proliferation of the cells. In general, a period of from about 10 minutes to about 24 hours should be sufficient. The stimulated cells then are provided to the individual as, for example, by injecting the cells to an appropriate in vivo locus. Suitable biocompatible progenitor cells may be obtained by any of the methods known in the art or described herein.

## REGENERATION OF DAMAGED OR DISEASED TISSUE

The morphogens of this invention may be used to repair diseased or damaged mammalian tissue. The tissue to be repaired is preferably assessed, and excess necrotic or interfering scar tissue removed as needed, by surgical, chemical, ablating or other methods known in the medical arts.

The morphogen then may be provided directly to the tissue locus as part of a sterile, biocompatible composition, either by surgical implantation or injection. Alternatively, a sterile, biocompatible composition containing morphogen-stimulated progenitor cells may be provided to the tissue locus. The existing tissue at the locus, whether diseased or damaged, provides the appropriate matrix to allow the proliferation and tissue-specific differentiation of progenitor cells. In addition, a damaged or diseased tissue locus, particularly one that has been further assaulted by surgical means, provides a morphogenically permissive environment. For some tissues, it is envisioned that systemic provision of the morphogen will be sufficient.

In some circumstances, particularly where tissu damage is extensive, the tissue may not b capable of providing a sufficient matrix for cell influx and proliferation. In these instances, it may be necessary to provide the morphogen or morphogen-stimulated progenitor cells to the tissue locus in association with a suitable, biocompatible formulated matrix, prepared by any of the means described below. The matrix preferably is tissue-specific, in vivo biodegradable, and comprises particles having dimensions within the range of 70-850$\mu$m, most preferably 150-420$\mu$m.

The morphogens of this invention also may be used to prevent or substantially inhibit scar tissue formation following an injury. If a morphogen is provided to a newly injured tissue locus, it can induce tissue morphogenesis at the locus, preventing the aggregation of migrating fibroblasts into non-differentiated connective tissue. The morphogen preferably is provided as a sterile pharmaceutical preparation injected into the tissue locus within five hours of the injury. Several non-limiting examples follow, illustrating the morphogens regenerate capabilities in different issues. The proteins of this invention previously have been shown to be capable of inducing cartilage and endochondral bone formation (See, for example U.S. Patent No. 5,011,691).

As an example, protein-induced morphogenesis of substantially injured liver tissue following a partial hepatectomy is disclosed. Variations on this general protocol may be used to test morphogen activity in other different tissues. The general method involves excising an essentially nonregenerating portion of a

tissue and providing the morphogen, preferably as a s luble pharmaceutical preparation to the excised tissue locus, closing the wound and examining the site at a future date. Like bone, liver has a potential to regenerate upon injury during post-fetal life.

Morphogen, (e.g., purified recombinant human OP-1, mature form), was solubilized (1 mg/ml) in 50% ethanol (or compatible solvent) containing 0.1% trifluoroacetic acid (or compatible acid). The injectable OP-1 solution was prepared by diluting one volume of OP-1/solvent-acid stock solution with 9 volumes of 0.2% rat serum albumin in sterile PBS (phosphate-buffered saline).

Growing rats or aged rats were anesthetized by using ketamine. Two of the liver lobes (left and right) were cut out (approximately 1/3 of the lobe) and the OP-1 was injected locally at multiple sites along the cut ends. The amount of OP-1 injected was 100 $\mu$g in 100 of PBS/RSA (phosphate buffered saline/rat serum albumin) injection buffer. Placebo samples are injection buffer without OP-1. Five rats in each group were used. The wound was closed and the rats were allowed to eat normal food and drink tap water.

After 12 days, the rats were sacrificed and liver regeneration was observed visually. The photomicrograph in Fig. 7 illustrates dramatically the regenerative effects of OP-1 on liver regeneration. The OP-1-injected group showed complete liver tissue regeneration and no sign remained of any cut in the liver (animal 2). By contrast, in the control group into which only PBS was injected only minimal regeneration was evidenced (animal 1). In addition, the incision remains in this sample.

As another example, the ability of the morphogens of this invention to induce dentinogenesis also was assessed. To date, the unpredictable response of dental pulp tissue to injury is a basic clinical problem in dentistry. Cynomolgus monkeys were chosen as primate models as monkeys are presumed to be more indicative of human dental biology than models based on lower non-primate mammals.

Using standard dental surgical procedures, small areas (e.g., 2mm) of dental pulps were surgically exposed by removing the enamel and dentin immediately above the pulp (by drilling) of sample teeth, performing a partial amputation of the coronal pulp tissue, inducing hemostasis, application of the pulp treatment, and sealing and filling the cavity by standard procedures.

Pulp treatments used were: OP-1 dispersed in a carrier matrix; carrier matrix alone and no treatment. Twelve teeth per animal (four for each treatment) were prepared, and two animals were used. At four weeks, teeth were extracted and processed histologically for analysis of dentin formation, and/or ground to analyze dentin mineralization. FIG.8 illustrates dramatically the effect of morphogen on osteodentin reparation. FIG. 8A is a photomicrograph of the control treatment (PBS) and shows little or no reparation. FIG. 8B is a photomicrograph of treatment with carrier alone, showing minimal reparation. By contrast, treatment with morphogen (FIG. 8C) shows significant reparation. The results of FIG. 8 indicate that OP-1-CM (OP-1 plus

carrier matrix) reliably induced formation f reparative or osteodentin bridg s on surgically exposed healthy dental pulps. By contrast, pulps treated with carrier matrix alone, or not treated failed to form reparative dentin.

As another example, the morphogen-induced regenerative effects on central nervous system (CNS) repair may be assessed using a rat brain stab model. Briefly, male Long Evans rats are anesthesized and the head area prepared for surgery. The calvariae is exposed using standard surgical procedures and a hole drilled toward the center of each lobe using a 0.035K wire, just piercing the calvariae. 25$\mu$l solutions containing either morphogen (OP-1, 25$\mu$g) or PBS then is provided to each of the holes by Hamilton syringe. Solutions are delivered to a depth approximately 3 mm below the surface, into the underlying cortex, corpus callosum and hippocampus. The skin then is sutured and the animal allowed to recover.

Three days post surgery, rats are sacrificed by decapitation and their brains processed for sectioning. Scar tissue formation is evaluated by immunofluoresence staining for glial fibrillary acidic protein, a marker protein for glial scarring, to qualitatively determine the degree of scar formation. Sections also are probed with anti-OP-1 antibodies to determine the presence of OP-1. Reduced levels of glial fibrillary acidic protein are anticipated in the tissue sections of animals treated with morphogen, evidencing the ability of morphogen to inhibit glial scar formation, thereby stimulating nerve regeneration.

## MORPHOGEN ACTIVITY MODULATION

Antibodies to morphogens of this invention have been identified in healthy human sera. In addition, implanting devices comprising morphogens (e.g., OP-1) have been discovered to induce an increase in anti-morphogen antibodies (e.g., anti-OP-1 antibodies). It is anticipated that these antibodies comprise part of the body's regulation of morphogen activity in vivo. The presence of the antibodies, and fluctuations in their levels, which are readily monitored, can provide a useful method for monitoring tissue stasis and tissue viability (e.g., identification of a pathological state). For example, standard radioimmunoassays or ELISA may be used to detect and quantify endogeous anti-morphogen antibodies in sera. Antibodies or other binding proteins capable of detecting anti-morphogen antibodies may be obtained using standard methodologies.

## MATRIX PREPARATION

The morphogens of this invention may be implanted surgically, dispersed in a biocompatible, preferably in vivo biodegradable matrix appropriately modified to provide a structure in which the morphogen may be dispersed and which allows the influx, differentiation and proliferation of migrating progenitor cells. The matrix also should provide signals capable of directing the tissue specificity of the differentiating cells, as well as a morphogenically permissive environment, being essentially free of growth inhibiting signals.

In the absence of these features the matrix does not appear to be suitable as part of a morphogenic composition. Recent studies on osteogenic devices

(morphogens dispersed within a formulated matrix) using matric s formulated from polylactic acid and/ r polyglycolic acid biopolymers, ceramics (a-tri-calcium-phosphate), r hydroxyapatite show that these materials, by themselves, are unable to provide the appropriate environment for inducing de novo endochondral bone formation in rats by themselves. In addition, matrices formulated from commercially available highly purified, reconstituted collagens or naturally-derived non-bone, species-specific collagen (e.g., from rat tail tendon) also are unsuccessful in inducing bone when implanted in association with an osteogenic protein. These matrices apparently lack specific structurally-related features which aid in directing the tissue specificity of the morphogen-stimulated, differentiating progenitor cells.

The formulated matrix may be shaped as desired in anticipation of surgery or may be shaped by the physician or technician during surgery. Thus, the material may be used in topical, subcutaneous, intraperitoneal, or intramuscular implants to repair tissue or to induce its growth de novo. The matrix preferably is biodegradable in vivo, being slowly absorbed by the body and replaced by new tissue growth, in the shape or very nearly in the shape of the implant.

Details of how to make and how to use the matrices useful in this invention are disclosed below.

## TISSUE-DERIVED MATRICES

Suitable biocompatible, in vivo biodegradable acellular matrices may be prepared from naturally-

ccurring tissue. The tissue is treated with suitable ag nts t substantially extract the cellular, nonstructural components of the tissue. The agents also should be capable of extracting any growth inhibiting components associated with the tissue. The resulting material is a porous, acellular matrix, substantially depleted in nonstructurally-associated components.

The matrix also may be further treated with agents that modify the matrix, increasing the number of pores and micropits on its surfaces. Those skilled in the art will know how to determine which agents are best suited to the extraction of nonstructural components for different tissues. For example, soft tissues such as liver and lung may be thin-sectioned and exposed to a nonpolar solvent such as, for example, 100% ethanol, to destroy the cellular structure of the tissue and extract nonstructural components. The material then is dried and pulverized to yield nonadherent porous particles. Structural tissues such as cartilage and dentin where collagen is the primary component may be demineralized and extracted with guanidine, essentially following the method of Sampath et al. (1983) PNAS 80:6591-6595. For example, pulverized and demineralized dentin is extracted with five volumes of 4M guanidine-HCl, 50mM Tris-HCl, pH 7.0 for 16 hours at 4°C. The suspension then is filtered. The insoluble material that remains is collected and used to fabricate the matrix. The material is mostly collagenous in manner. It is devoid of morphogenic activity. The matrix particles may further be treated with a collagen fibril-modifying agent that extracts potentially unwanted components from the matrix, and alters the surface structure of the matrix material.

Useful agents includ acids, organic s lvents or heated aqueous media. A detailed description of thes matrix treatments are disclos d in U.S. Patent No. 4,975,526 and PCT publication US90/00912, published September 7, 1990 (WO90/10018).

The currently most preferred agent is a heated aqueous fibril-modifying medium such as water, to increase the matrix particle surface area and porosity. The currently most preferred aqueous medium is an acidic aqueous medium having a pH of less than about 4.5, e.g., within the range of about pH 2 - pH 4 which may help to "swell" the collagen before heating. 0.1% acetic acid, which has a pH of about 3, currently is most preferred. 0.1 M acetic acid also may be used.

Various amounts of delipidated, demineralized guanidine-extracted bone collagen are heated in the aqueous medium (1g matrix/30ml aqueous medium) under constant stirring in a water jacketed glass flask, and maintained at a given temperature for a predetermined period of time. Preferred treatment times are about one hour, although exposure times of between about 0.5 to two hours appear acceptable. The temperature employed is held constant at a temperature within the range of about 37°C to 65°C. The currently preferred heat treatment temperature is within the range of about 45°C to 60°C.

After the heat treatment, the matrix is filtered, washed, lyophilized and used for implant. Where an acidic aqueous medium is used, the matrix also is preferably neutralized prior to washing and lyophilization. A currently preferred neutralization buffer is a 200mM sodium phosphate buffer, pH 7.0. To

neutraliz the matrix, the matrix preferably first is allowed to cool following thermal treatment, the acidic aqueous medium (e.g., 0.1% acetic acid) th n is removed and replaced with the neutralization buffer and the matrix agitated for about 30 minutes. The neutralization buffer then may be removed and the matrix washed and lyophilized.

Other useful fibril-modifying treatments include acid treatments (e.g., trifluoroacetic acid and hydrogen fluoride) and solvent treatments such as dichloromethane, acetonitrile, isopropanol and chloroform, as well as particular acid/solvent combinations.

After contact with the fibril-modifying agent, the treated matrix may be washed to remove any extracted components, following a form of the procedure set forth below:

1. Suspend matrix preparation in TBS (Tris-buffered saline) 1g/200 ml and stir at 4°C for 2 hrs; or in 6 M urea, 50 mM Tris-HCl, 500 mM NaCl, pH 7.0 (UTBS) or water and stir at room temperature (RT) for 30 minutes (sufficient time to neutralize the pH);

2. Centrifuge and repeat wash step; and

3. Centrifuge; discard supernatant; water wash residue; and then lyophilize.

## SYNTHETIC TISSUE-SPECIFIC MATRICES

In addition to the naturally-derived tissue-

specific matrices described above, useful tissue-specific matrices may be formulated synthetically if appropriately modified. These porous biocompatible, in vivo biodegradable synthetic matrices are disclosed in PCT publication US91/03603, published December 12, 1991 (WO91/18558), the disclosure of which is hereby incorporated by reference. Briefly, the matrix comprises a porous crosslinked structural polymer of biocompatible, biodegradable collagen and appropriate, tissue-specific glycosaminoglycans as tissue-specific cell attachment factors. Collagen derived from a number of sources may be suitable for use in these synthetic matrices, including insoluble collagen, acid-soluble collagen, collagen soluble in neutral or basic aqueous solutions, as well as those collagens which are commercially available.

Glycosaminoglycans (GAGs) or mucopolysaccharides are hexosamine-containing polysaccharides of animal origin that have a tissue specific distribution, and therefore may be used to help determine the tissue specificity of the morphogen-stimulated differentiating cells. Reaction with the GAGs also provides collagen with another valuable property, i.e., inability to provoke an immune reaction (foreign body reaction) from an animal host.

Chemically, GAGs are made up of residues of hexoseamines glycosidically bound and alternating in a more-or-less regular manner with either hexouronic acid or hexose moieties (see, e.g., Dodgson et al. in Carbohydrate Metabolism and its Disorders (Dickens et al., eds.) Vol. 1, Academic Press (1968)). Useful GAGs include hyaluronic acid, heparin, heparin sulfate, chondroitin 6-sulfate, chondroitin 4-sulfate, dermatan

sulfat , and keratin sulfate. Other GAGs are suitable for forming th matrix described herein, and th se skilled in the art will either know or be able to ascertain other suitable GAGs using no more than routine experimentation. For a more detailed description of mucopolysaccharides, see Aspinall, Polysaccharides, Pergamon Press, Oxford (1970). For example, as disclosed in U.S. Application Serial No. 529,852, chondroitin-6-sulfate can be used where endochondral bone formation is desired. Heparin sulfate, on the other hand, may be used to formulate synthetic matrices for use in lung tissue repair.

Collagen can be reacted with a GAG in aqueous acidic solutions, preferably in diluted acetic acid solutions. By adding the GAG dropwise into the aqueous collagen dispersion, coprecipitates of tangled collagen fibrils coated with GAG results. This tangled mass of fibers then can be homogenized to form a homogeneous dispersion of fine fibers and then filtered and dried.

Insolubility of the collagen-GAG products can be raised to the desired degree by covalently cross-linking these materials, which also serves to raise the resistance to resorption of these materials. In general, any covalent cross-linking method suitable for cross-linking collagen also is suitable for cross-linking these composite materials, although crosslinking by a dehydrothermal process is preferred.

When dry, the crosslinked particles are essentially spherical, with diameters of about 500 μm. Scanning electron miscroscopy shows pores of about 20 μm on the surface and 40 μm on the interior. The interior is made up of both fibrous and sheet-like

structures, providing surfaces for cell attachment. The voids interconnect, providing access to the cells throughout the interior of the particle. The material appears to be roughly 99.5% void volume, making the material very efficient in terms of the potential cell mass that can be grown per gram of microcarrier.

The morphogens described herein can be combined and dispersed in an appropriately modified tissue-specific matrix using any of the methods described below:

1. Ethanol Precipitation

Matrix is added to the morphogen dissolved in guanidine-HCl. Samples are vortexed and incubated at a low temperature. Samples are then further vortexed. Cold absolute ethanol is added to the mixture which is then stirred and incubated. After centrifugation (microfuge, high speed) the supernatant is discarded. The matrix is washed with cold concentrated ethanol in water and then lyophilized.

2. Acetonitrile Trifluoroacetic Acid Lyophilization

In this procedure, morphogen in an acetonitrile trifluroacetic acid (ACN/TFA solution is added to the carrier material. Samples are vigorously vortexed many times and then lyophilized.

3. Buffered Saline Lyophilization

Morphogen preparations in physiological saline may also be vortexed with the matrix and lyophilized to

produce morphogenically active material.

## BIOASSAY

The following sets forth various procedures for evaluating the in vivo morphogenic utility of the morphogens and morphogenic compositions of this invention. The proteins and compositions may be injected or surgically implanted in a mammal, following any of a number of procedures well known in the art. For example, surgical implant bioassays may be performed essentially following the procedure of Sampath et al. (1983) PNAS 80:6591-6595.

### Histological Evaluation

Histological sectioning and staining is preferred to determine the extent of morphogenesis in vivo, particularly in tissue repair procedures. Excised implants are fixed in Bouins Solution, embedded in paraffin, and cut into 6-8 μm sections. Staining with toluidine blue or hemotoxylin/eosin demonstrates clearly the ultimate development of the new tissue. Twelve day implants are usually sufficient to determine whether the implants contain newly induced tissue.

Successful implants exhibit a controlled progression through the stages of induced tissue development allowing one to identify and follow the tissue-specific events that occur. For example, in endochondral bone formation the stages include: (1) leukocytes on day one; (2) mesenchymal cell migration and proliferation on days two and three; (3) chondrocyte appearance on days five and six;

(4) cartilage matrix formation on day seven; (5) cartilage calcification on day eight; (6) vascular invasion, appearance of osteoblasts, and formation of n w bone on days nine and ten; (7) appearance of osteoblastic and bone remodeling and dissolution of the implanted matrix on days twelve to eighteen; and (8) hematopoietic bone marrow differentiation in the ossicle on day twenty-one.

Biological Markers

In addition to histological evaluation, biological markers may be used as a marker for tissue morphogenesis. Useful markers include tissue-specific enzymes whose activities may be assayed (e.g., spectrophotometrically) after homogenization of the implant. These assays may be useful for quantitation and for obtaining an estimate of tissue formation quickly after the implants are removed from the animal. For example, alkaline phosphatase activity may be used as a marker for osteogenesis.

Incorporation of systemically provided morphogens may be followed using tagged morphogens (e.g., radioactively labelled) and determining their localization in new tissue, and/or by monitoring their disappearance from the circulatory system using a standard pulse-chase labeling protocol. The morphogen also may be provided with a tissue-specific molecular tag, whose uptake may be monitored and correlated with the concentration of morphogen provided. As an example, ovary removal in female rats results in reduced bone alkaline phosphatase activity, rendering the rats predisposed to osteoporosis. If the female rats now are provided with a morphogen, e.g., OP-1, a

reduction in the systemic concentration of calcium ($CA^{2+}$) is seen, which correlates with the presence of the provid d morphogen and can be shown to correspond to increased alkaline phosphatase activity.

The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i)APPLICANT: COHEN, CHARLES M.
KUBERASAMPATH, THANGAVEL
PANG, ROY H.L.
OPPERMANN, HERMANN
RUEGER, DAVID C.

(ii) TITLE OF INVENTION: PROTEIN-INDUCED MORPHOGENESIS

(iii) NUMBER OF SEQUENCES: 23

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: TESTA, HURWITZ & THIBEAULT
(B) STREET: 53 STATE STREET
(C) CITY: BOSTON
(D) STATE: MASSACHUSETTS
(E) COUNTRY: U.S.A.
(F) ZIP: 02109

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 667,274
(B) FILING DATE: 11-MAR-1991

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 752,764
(B) FILING DATE: 30-AUG-1991

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 97 amino acids
(B) TYPE: amino acids
(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: Generic Sequence 1

(D) OTHER INFORMATION: Each Xaa indicates one of the 20 naturally-occurring L-isomer, α-amino acids or a derivative thereof.

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Xaa Xaa Xaa Xaa Xaa Xaa
1 5
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
10 15
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
20 25
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
30 35
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
40 45 50
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
55 60
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
65 70
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
75 80
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
85 90
Xaa Cys Xaa
95

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 97 amino acids

(B) TYPE: amino acids

(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: Generic Sequence 2

(D) OTHER INFORMATION: Each Xaa indicates one of the 20 naturally-occurring L-isomer, α-amino acids or a derivative thereof.

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Xaa Xaa Xaa Xaa Xaa Xaa
1 5
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
10 15
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
20 25
Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
30 35
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
40 45 50
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
55 60
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
65 70
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
75 80
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
85 90
Xaa Cys Xaa
95

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 97 amino acids

(B) TYPE: amino acids

(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: Generic Sequenc 3

(D) OTHER INFORMATION: wherein each Xaa is independently selected from a group of one or more specified amino acids as defined in the specification.

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Leu Tyr Val Xaa Phe
1 5

Xaa Xaa Xaa Gly Trp Xaa Xaa Trp Xaa
10

Xaa Ala Pro Gly Xaa Xaa Xaa Ala
15 20

Xaa Tyr Cys Xaa Gly Xaa Cys Xaa
25 30

Xaa Pro Xaa Xaa Xaa Xaa Xaa
35

Xaa Xaa Xaa Asn His Ala Xaa Xaa
40 45

Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa
50

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
55 60

Cys Xaa Pro Xaa Xaa Xaa Xaa Xaa
65

Xaa Xaa Xaa Leu Xaa Xaa Xaa
70 75

Xaa Xaa Xaa Xaa Val Xaa Leu Xaa
80

Xaa Xaa Xaa Xaa Met Xaa Val Xaa
85 90

Xaa Cys Gly Cys Xaa
95

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 102 amino acids
(B) TYPE: amino acids
(C) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(ix) FEATURE:
(A) NAME: Generic Sequence 4
(D) OTHER INFORMATION: wherein each Xaa is independently selected from a group of one or more specified amino acids as defined in the specification.

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```
Cys Xaa Xaa Xaa Xaa Leu Tyr Val Xaa Phe
 1               5                  10
Xaa Xaa Xaa Gly Trp Xaa Xaa Trp Xaa
                15
Xaa Ala Pro Xaa Gly Xaa Xaa Ala
 20                  25
Xaa Tyr Cys Xaa Gly Xaa Cys Xaa
          30                  35
Xaa Pro Xaa Xaa Xaa Xaa Xaa
                40
Asn Xaa Xaa Asn His Ala Xaa Xaa
          45                  50
Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa
                55
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
     60                  65
Cys Xaa Pro Xaa Xaa Xaa Xaa Xaa
                70
```

Xaa Xaa Xaa Leu Xaa Xaa Xaa
75 80
Xaa Xaa Xaa Xaa Val Xaa Leu Xaa
85
Xaa Xaa Xaa Xaa Met Xaa Val Xaa
90 95
Xaa Cys Gly Cys Xaa
100

(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 139 amino acids
(B) TYPE: amino acids
(C) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(ix) FEATURE:
(A) NAME: hOP-1 (mature form)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Ser Thr Gly Ser Lys Gln Arg Ser Gln
1 5
Asn Arg Ser Lys Thr Pro Lys Asn Gln
10 15
Glu Ala Leu Arg Met Ala Asn Val Ala
20 25
Glu Asn Ser Ser Ser Asp Gln Arg Gln
30 35
Ala Cys Lys Lys His Glu Leu Tyr Val
40 45
Ser Phe Arg Asp Leu Gly Trp Gln Asp
50
Trp Ile Ile Ala Pro Glu Gly Tyr Ala
55 60
Ala Tyr Tyr Cys Glu Gly Glu Cys Ala
65 70

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| Phe | Pro | Leu | Asn | Ser | Tyr | Met | Asn | Ala |
| | | 75 | | | | | 80 | |
| Thr | Asn | His | Ala | Ile | Val | Gln | Thr | Leu |
| | | | 85 | | | | | 90 |
| Val | His | Phe | Ile | Asn | Pro | Glu | Thr | Val |
| | | | | 95 | | | | |
| Pro | Lys | Pro | Cys | Cys | Ala | Pro | Thr | Gln |
| 100 | | | | | 105 | | | |
| Leu | Asn | Ala | Ile | Ser | Val | Leu | Tyr | Phe |
| | 110 | | | | | 115 | | |
| Asp | Asp | Ser | Ser | Asn | Val | Ile | Leu | Lys |
| | | 120 | | | | | 125 | |
| Lys | Tyr | Arg | Asn | Met | Val | Val | Arg | Ala |
| | | | 130 | | | | | 135 |
| Cys | Gly | Cys | His | | | | | |

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 139 amino acids

(B) TYPE: amino acids

(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: mOP-1 (mature form)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| Ser | Thr | Gly | Gly | Lys | Gln | Arg | Ser | Gln |
| 1 | | | | 5 | | | | |
| Asn | Arg | Ser | Lys | Thr | Pro | Lys | Asn | Gln |
| 10 | | | | | 15 | | | |
| Glu | Ala | Leu | Arg | Met | Ala | Ser | Val | Ala |
| | 20 | | | | | 25 | | |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| Glu | Asn | Ser | Ser | Ser | Asp | Gln | Arg | Gln |
| | | 30 | | | | | 35 | |
| Ala | Cys | Lys | Lys | His | Glu | Leu | Tyr | Val |
| | | | 40 | | | | | 45 |
| Ser | Phe | Arg | Asp | Leu | Gly | Trp | Gln | Asp |
| | | | | 50 | | | | |
| Trp | Ile | Ile | Ala | Pro | Glu | Gly | Tyr | Ala |
| 55 | | | | | 60 | | | |
| Ala | Tyr | Tyr | Cys | Glu | Gly | Glu | Cys | Ala |
| | 65 | | | | | 70 | | |
| Phe | Pro | Leu | Asn | Ser | Tyr | Met | Asn | Ala |
| | | 75 | | | | | 80 | |
| Thr | Asn | His | Ala | Ile | Val | Gln | Thr | Leu |
| | | | 85 | | | | | 90 |
| Val | His | Phe | Ile | Asn | Pro | Asp | Thr | Val |
| | | | | 95 | | | | |
| Pro | Lys | Pro | Cys | Cys | Ala | Pro | Thr | Gln |
| 100 | | | | | 105 | | | |
| Leu | Asn | Ala | Ile | Ser | Val | Leu | Tyr | Phe |
| | 110 | | | | | 115 | | |
| Asp | Asp | Ser | Ser | Asn | Val | Ile | Leu | Lys |
| | | 120 | | | | | 125 | |
| Lys | Tyr | Arg | Asn | Met | Val | Val | Arg | Ala |
| | | | 130 | | | | | 135 |
| Cys | Gly | Cys | His | | | | | |

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 139 amino acids

(B) TYPE: amino acids

(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: hOP-2 (mature form)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| Ala | Val | Arg | Pro | Leu | Arg | Arg | Arg | Gln |
| Pro | Lys | Lys | Ser | Asn | Glu | Leu | Pro | Gln |
| Ala | Asn | Arg | Leu | Pro | Gly | Ile | Phe | Asp |
| Asp | Val | His | Gly | Ser | His | Gly | Arg | Gln |
| Val | Cys | Arg | Arg | His | Glu | Leu | Tyr | Val |
| Ser | Phe | Gln | Asp | Leu | Gly | Trp | Leu | Asp |
| Trp | Val | Ile | Ala | Pro | Gln | Gly | Tyr | Ser |
| Ala | Tyr | Tyr | Cys | Glu | Gly | Glu | Cys | Ser |
| Phe | Pro | Leu | Asp | Ser | Cys | Met | Asn | Ala |
| Thr | Asn | His | Ala | Ile | Leu | Gln | Ser | Leu |
| Val | His | Leu | Met | Lys | Pro | Asn | Ala | Val |
| Pro | Lys | Ala | Cys | Cys | Ala | Pro | Thr | Lys |
| Leu | Ser | Ala | Thr | Ser | Val | Leu | Tyr | Tyr |
| Asp | Ser | Ser | Asn | Asn | Val | Ile | Leu | Arg |
| Lys | His | Arg | Asn | Met | Val | Val | Lys | Ala |
| Cys | Gly | Cys | His | | | | | |

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 139 amino acids

(B) TYPE: amino acids

(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: mOP-2 (mature form)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| Ala | Ala | Arg | Pro | Leu | Lys | Arg | Arg | Gln |
| 1 | | | | 5 | | | | |
| Pro | Lys | Lys | Thr | Asn | Glu | Leu | Pro | His |
| 10 | | | | | 15 | | | |
| Pro | Asn | Lys | Leu | Pro | Gly | Ile | Phe | Asp |
| | 20 | | | | | 25 | | |
| Asp | Gly | His | Gly | Ser | Arg | Gly | Arg | Glu |
| | | 30 | | | | | 35 | |
| Val | Cys | Arg | Arg | His | Glu | Leu | Tyr | Val |
| | | | 40 | | | | | 45 |
| Arg | Phe | Arg | Asp | Leu | Gly | Trp | Leu | Asp |
| | | | | 50 | | | | |
| Trp | Val | Ile | Ala | Pro | Gln | Gly | Tyr | Ser |
| 55 | | | | | 60 | | | |
| Ala | Tyr | Tyr | Cys | Glu | Gly | Glu | Cys | Ala |
| | 65 | | | | | 70 | | |
| Phe | Pro | Leu | Asp | Ser | Cys | Met | Asn | Ala |
| | | 75 | | | | | 80 | |
| Thr | Asn | His | Ala | Ile | Leu | Gln | Ser | Leu |
| | | | 85 | | | | | 90 |
| Val | His | Leu | Met | Lys | Pro | Asp | Val | Val |
| | | | | 95 | | | | |
| Pro | Lys | Ala | Cys | Cys | Ala | Pro | Thr | Lys |
| 100 | | | | | 105 | | | |

```
Leu  Ser  Ala  Thr  Ser  Val  Leu  Tyr  Tyr
     110                     115
Asp  Ser  Ser  Asn  Asn  Val  Ile  Leu  Arg
          120                     125
Lys  His  Arg  Asn  Met  Val  Val  Lys  Ala
               130                     135
Cys  Gly  Cys  His
```

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 96 amino acids

(B) TYPE: amino acids

(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: CBMP-2A(fx)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

```
Cys Lys Arg His Pro Leu Tyr Val Asp Phe Ser
 1               5                  10
Asp Val Gly Trp Asn Asp Trp Ile Val Ala Pro
            15                  20
Pro Gly Tyr His Ala Phe Tyr Cys His Gly Glu
        25                  30
Cys Pro Phe Pro Leu Ala Asp His Leu Asn Ser
    35                  40
Thr Asn His Ala Ile Val Gln Thr Leu Val Asn
45                  50                  55
Ser Val Asn Ser Lys Ile Pro Lys Ala Cys Cys
                60                  65
Val Pro Thr Glu Leu Ser Ala Ile Ser Met Leu
            70                  75
Tyr Leu Asp Glu Asn Glu Lys Val Val Leu Lys
        80                  85
```

```
Asn Tyr Gln Asp Met Val Val Glu Gly Cys Gly
     90                  95
Cys Arg
100
```

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 101 amino acids

(B) TYPE: amino acids

(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: CBMP-2B(fx)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

```
                          Cys Arg Arg His Ser
                            1               5
Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asn
                   10                  15
Asp Trp Ile Val Ala Pro Pro Gly Tyr Gln Ala
              20                  25
Phe Tyr Cys His Gly Asp Cys Pro Phe Pro Leu
         30                  35
Ala Asp His Leu Asn Ser Thr Asn His Ala Ile
     40                  45
Val Gln Thr Leu Val Asn Ser Val Asn Ser Ser
 50                  55                  60
Ile Pro Lys Ala Cys Cys Val Pro Thr Glu Leu
                   65                  70
Ser Ala Ile Ser Met Leu Tyr Leu Asp Glu Tyr
              75                  80
Asp Lys Val Val Leu Lys Asn Tyr Gln Glu Met
         85                  90
```

Val Val Glu Gly Cys Gly Cys Arg
95 100

(2) INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 102 amino acids
(B) TYPE: amino acids
(C) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(ix) FEATURE:
(A) NAME: DPP(fx)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Cys Arg Arg His Ser Leu Tyr Val Asp Phe Ser
1 5 10
Asp Val Gly Trp Asp Asp Trp Ile Val Ala Pro
15 20
Leu Gly Tyr Asp Ala Tyr Tyr Cys His Gly Lys
25 30
Cys Pro Phe Pro Leu Ala Asp His Phe Asn Ser
35 40
Thr Asn His Ala Val Val Gln Thr Leu Val Asn
45 50 55
Asn Asn Asn Pro Gly Lys Val Pro Lys Ala Cys
60 65
Cys Val Pro Thr Gln Leu Asp Ser Val Ala Met
70 75
Leu Tyr Leu Asn Asp Gln Ser Thr Val Val Leu
80 85
Lys Asn Tyr Gln Glu Met Thr Val Val Gly Cys
90 95
Gly Cys Arg
100

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 102 amin acids

(B) TYPE: amino acids

(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: Vgl(fx)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Cys Lys Lys Arg His Leu Tyr Val Glu Phe Lys
1 5 10
Asp Val Gly Trp Gln Asn Trp Val Ile Ala Pro
15 20
Gln Gly Tyr Met Ala Asn Tyr Cys Tyr Gly Glu
25 30
Cys Pro Tyr Pro Leu Thr Glu Ile Leu Asn Gly
35 40
Ser Asn His Ala Ile Leu Gln Thr Leu Val His
45 50 55
Ser Ile Glu Pro Glu Asp Ile Pro Leu Pro Cys
60 65
Cys Val Pro Thr Lys Met Ser Pro Ile Ser Met
70 75
Leu Phe Tyr Asp Asn Asn Asp Asn Val Val Leu
80 85
Arg His Tyr Glu Asn Met Ala Val Asp Glu Cys
90 95
Gly Cys Arg
100

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 102 amino acids

(B) TYPE: amino acids

(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: Vgr-1(fx)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

```
Cys Lys Lys His Glu Leu Tyr Val Ser Phe Gln
 1               5                  10
Asp Val Gly Trp Gln Asp Trp Ile Ile Ala Pro
            15                  20
Xaa Gly Tyr Ala Ala Asn Tyr Cys Asp Gly Glu
        25                  30
Cys Ser Phe Pro Leu Asn Ala His Met Asn Ala
    35                  40
Thr Asn His Ala Ile Val Gln Thr Leu Val His
45                  50                  55
Val Met Asn Pro Glu Tyr Val Pro Lys Pro Cys
                60                  65
Cys Ala Pro Thr Lys Val Asn Ala Ile Ser Val
            70                  75
Leu Tyr Phe Asp Asp Asn Ser Asn Val Ile Leu
        80                  85
Lys Lys Tyr Arg Asn Met Val Val Arg Ala Cys
    90                  95
Gly Cys His
100
```

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 106 amino acids
(B) TYPE: protein
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(F) TISSUE TYPE: BRAIN

(ix) FEATURE:
(D) OTHER INFORMATION:
/product= "GDF-1 (fx)"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Cys Arg Ala Arg Arg Leu Tyr Val Ser Phe Arg Glu Val Gly
1 5 10

Trp His Arg Trp Val Ile Ala Pro Arg Gly Phe Leu Ala Asn Tyr
15 20 25

Cys Gln Gly Gln Cys Ala Leu Pro Val Ala Leu Ser Gly Ser Gly
30 35 40

Gly Pro Pro Ala Leu Asn His Ala Val Leu Arg Ala Leu Met His
45 50 55

Ala Ala Ala Pro Gly Ala Ala Asp Leu Pro Cys Cys Val Pro Ala
60 65 70

Arg Leu Ser Pro Ile Ser Val Leu Phe Phe Asp Asn Ser Asp Asn
75 80 85

Val Val Leu Arg Gln Tyr Glu Asp Met Val Val Asp Glu Cys Gly
90 95 100

Cys Arg
105

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Cys Xaa Xaa Xaa Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1822 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:
(A) ORGANISM: HOMO SAPIENS
(F) TISSUE TYPE: HIPPOCAMPUS

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 49..1341
(D) OTHER INFORMATION:/standard_name= "hOP1"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

```
GGTGCGGGCC CGGAGCCCGG AGCCCGGGTA GCGCGTAGAG CCGGCGCG ATG CAC GTG      57
                                                      Met His Val
                                                        1

CGC TCA CTG CGA GCT GCG GCG CCG CAC AGC TTC GTG GCG CTC TGG GCA      105
Arg Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala Leu Trp Ala
  5                  10                  15

CCC CTG TTC CTG CTG CGC TCC GCC CTG GCC GAC TTC AGC CTG GAC AAC      153
Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser Leu Asp Asn
 20                  25                  30                  35

GAG GTG CAC TCG AGC TTC ATC CAC CGG CGC CTC CGC AGC CAG GAG CGG      201
Glu Val His Ser Ser Phe Ile His Arg Arg Leu Arg Ser Gln Glu Arg
                 40                  45                  50

CGG GAG ATG CAG CGC GAG ATC CTC TCC ATT TTG GGC TTG CCC CAC CGC      249
Arg Glu Met Gln Arg Glu Ile Leu Ser Ile Leu Gly Leu Pro His Arg
            55                  60                  65

CCG CGC CCG CAC CTC CAG GGC AAG CAC AAC TCG GCA CCC ATG TTC ATG      297
Pro Arg Pro His Leu Gln Gly Lys His Asn Ser Ala Pro Met Phe Met
        70                  75                  80

CTG GAC CTG TAC AAC GCC ATG GCG GTG GAG GAG GGC GGC GGG CCC GGC      345
Leu Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Gly Gly Gly Pro Gly
    85                  90                  95

GGC CAG GGC TTC TCC TAC CCC TAC AAG GCC GTC TTC AGT ACC CAG GGC      393
Gly Gln Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser Thr Gln Gly
100                 105                 110                 115
```

```
CCC CCT CTG GCC AGC CTG CAA GAT AGC CAT TTC CTC ACC GAC GCC GAC          441
Pro Pro Leu Ala Ser Leu Gln Asp Ser His Phe Leu Thr Asp Ala Asp
                120                 125                 130

ATG GTC ATG AGC TTC GTC AAC CTC GTG GAA CAT GAC AAG GAA TTC TTC          489
Met Val Met Ser Phe Val Asn Leu Val Glu His Asp Lys Glu Phe Phe
            135                 140                 145

CAC CCA CGC TAC CAC CAT CGA GAG TTC CGG TTT GAT CTT TCC AAG ATC          537
His Pro Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu Ser Lys Ile
        150                 155                 160

CCA GAA GGG GAA GCT GTC ACG GCA GCC GAA TTC CGG ATC TAC AAG GAC          585
Pro Glu Gly Glu Ala Val Thr Ala Ala Glu Phe Arg Ile Tyr Lys Asp
    165                 170                 175

TAC ATC CGG GAA CGC TTC GAC AAT GAG ACG TTC CGG ATC AGC GTT TAT          633
Tyr Ile Arg Glu Arg Phe Asp Asn Glu Thr Phe Arg Ile Ser Val Tyr
180                 185                 190                 195

CAG GTG CTC CAG GAG CAC TTG GGC AGG GAA TCG GAT CTC TTC CTG CTC          681
Gln Val Leu Gln Glu His Leu Gly Arg Glu Ser Asp Leu Phe Leu Leu
                200                 205                 210

GAC AGC CGT ACC CTC TGG GCC TCG GAG GAG GGC TGG CTG GTG TTT GAC          729
Asp Ser Arg Thr Leu Trp Ala Ser Glu Glu Gly Trp Leu Val Phe Asp
            215                 220                 225

ATC ACA GCC ACC AGC AAC CAC TGG GTG GTC AAT CCG CGG CAC AAC CTG          777
Ile Thr Ala Thr Ser Asn His Trp Val Val Asn Pro Arg His Asn Leu
        230                 235                 240

GGC CTG CAG CTC TCG GTG GAG ACG CTG GAT GGG CAG AGC ATC AAC CCC          825
Gly Leu Gln Leu Ser Val Glu Thr Leu Asp Gly Gln Ser Ile Asn Pro
    245                 250                 255

AAG TTG GCG GGC CTG ATT GGG CGG CAC GGG CCC CAG AAC AAG CAG CCC          873
Lys Leu Ala Gly Leu Ile Gly Arg His Gly Pro Gln Asn Lys Gln Pro
260                 265                 270                 275

TTC ATG GTG GCT TTC TTC AAG GCC ACG GAG GTC CAC TTC CGC AGC ATC          921
Phe Met Val Ala Phe Phe Lys Ala Thr Glu Val His Phe Arg Ser Ile
                280                 285                 290

CGG TCC ACG GGG AGC AAA CAG CGC AGC CAG AAC CGC TCC AAG ACG CCC          969
Arg Ser Thr Gly Ser Lys Gln Arg Ser Gln Asn Arg Ser Lys Thr Pro
            295                 300                 305

AAG AAC CAG GAA GCC CTG CGG ATG GCC AAC GTG GCA GAG AAC AGC AGC         1017
Lys Asn Gln Glu Ala Leu Arg Met Ala Asn Val Ala Glu Asn Ser Ser
        310                 315                 320
```

```
AGC GAC CAG AGG CAG GCC TGT AAG AAG CAC GAG CTG TAT GTC AGC TTC      1065
Ser Asp Gln Arg Gln Ala Cys Lys Lys His Glu Leu Tyr Val Ser Phe
    325                 330                 335

CGA GAC CTG GGC TGG CAG GAC TGG ATC ATC GCG CCT GAA GGC TAC GCC      1113
Arg Asp Leu Gly Trp Gln Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala
340                 345                 350                 355

GCC TAC TAC TGT GAG GGG GAG TGT GCC TTC CCT CTG AAC TCC TAC ATG      1161
Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met
                360                 365                 370

AAC GCC ACC AAC CAC GCC ATC GTG CAG ACG CTG GTC CAC TTC ATC AAC      1209
Asn Ala Thr Asn His Ala Ile Val Gln Thr Leu Val His Phe Ile Asn
            375                 380                 385

CCG GAA ACG GTG CCC AAG CCC TGC TGT GCG CCC ACG CAG CTC AAT GCC      1257
Pro Glu Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gln Leu Asn Ala
        390                 395                 400

ATC TCC GTC CTC TAC TTC GAT GAC AGC TCC AAC GTC ATC CTG AAG AAA      1305
Ile Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile Leu Lys Lys
    405                 410                 415

TAC AGA AAC ATG GTG GTC CGG GCC TGT GGC TGC CAC TAGCTCCTCC           1351
Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His
420                 425                 430

GAGAATTCAG ACCCTTTGGG GCCAAGTTTT TCTGGATCCT CCATTGCTCG CCTTGGCCAG    1411

GAACCAGCAG ACCAACTGCC TTTTGTGAGA CCTTCCCCTC CCTATCCCCA ACTTTAAAGG    1471

TGTGAGAGTA TTAGGAAACA TGAGCAGCAT ATGGCTTTTG ATCAGTTTTT CAGTGGCAGC    1531

ATCCAATGAA CAAGATCCTA CAAGCTGTGC AGGCAAAACC TAGCAGGAAA AAAAAACAAC    1591

GCATAAAGAA AAATGGCCGG GCCAGGTCAT TGGCTGGGAA GTCTCAGCCA TGCACGGACT    1651

CGTTTCCAGA GGTAATTATG AGCGCCTACC AGCCAGGCCA CCCAGCCGTG GGAGGAAGGG    1711

GGCGTGGCAA GGGGTGGGCA CATTGGTGTC TGTGCGAAAG GAAAATTGAC CCGGAAGTTC    1771

CTGTAATAAA TGTCACAATA AAACGAATGA ATGAAAAAAA AAAAAAAAAA A              1822
```

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 431 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:
(D) OTHER INFORMATION: /Product="OP1-PP"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Met His Val Arg Ser Leu Arg Ala Ala Pro His Ser Phe Val Ala
1 5 10 15

Leu Trp Ala Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser
20 25 30

Leu Asp Asn Glu Val His Ser Ser Phe Ile His Arg Arg Leu Arg Ser
35 40 45

Gln Glu Arg Arg Glu Met Gln Arg Glu Ile Leu Ser Ile Leu Gly Leu
50 55 60

Pro His Arg Pro Arg Pro His Leu Gln Gly Lys His Asn Ser Ala Pro
65 70 75 80

Met Phe Met Leu Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Gly Gly
85 90 95

Gly Pro Gly Gly Gln Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser
100 105 110

Thr Gln Gly Pro Pro Leu Ala Ser Leu Gln Asp Ser His Phe Leu Thr
115 120 125

Asp Ala Asp Met Val Met Ser Phe Val Asn Leu Val Glu His Asp Lys
130 135 140

Glu Phe Phe His Pro Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu
145 150 155 160

Ser Lys Ile Pro Glu Gly Glu Ala Val Thr Ala Ala Glu Phe Arg Ile
165 170 175

Tyr Lys Asp Tyr Ile Arg Glu Arg Phe Asp Asn Glu Thr Phe Arg Ile
180 185 190

Ser Val Tyr Gln Val Leu Gln Glu His Leu Gly Arg Glu Ser Asp Leu
195 200 205

Phe Leu Leu Asp Ser Arg Thr Leu Trp Ala Ser Glu Glu Gly Trp Leu
210 215 220

Val Phe Asp Ile Thr Ala Thr Ser Asn His Trp Val Val Asn Pro Arg
225 230 235 240

His Asn Leu Gly Leu Gln Leu Ser Val Glu Thr Leu Asp Gly Gln Ser
245 250 255

```
Ile Asn Pr  Lys Leu Ala Gly Leu Ile Gly Arg His Gly Pro Gln Asn
            260                 265                 270

Lys Gln Pro Phe Met Val Ala Phe Phe Lys Ala Thr Glu Val His Phe
        275                 280                 285

Arg Ser Ile Arg Ser Thr Gly Ser Lys Gln Arg Ser Gln Asn Arg Ser
    290                 295                 300

Lys Thr Pro Lys Asn Gln Glu Ala Leu Arg Met Ala Asn Val Ala Glu
305                 310                 315                 320

Asn Ser Ser Ser Asp Gln Arg Gln Ala Cys Lys Lys His Glu Leu Tyr
                325                 330                 335

Val Ser Phe Arg Asp Leu Gly Trp Gln Asp Trp Ile Ile Ala Pro Glu
            340                 345                 350

Gly Tyr Ala Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn
        355                 360                 365

Ser Tyr Met Asn Ala Thr Asn His Ala Ile Val Gln Thr Leu Val His
    370                 375                 380

Phe Ile Asn Pro Glu Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gln
385                 390                 395                 400

Leu Asn Ala Ile Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile
                405                 410                 415

Leu Lys Lys Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His
            420                 425                 430
```

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1873 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:
(A) ORGANISM: MURIDAE
(F) TISSUE TYPE: EMBRYO

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 104..1393
(D) OTHER INFORMATION: /note= "MOP1 (CDNA)"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

```
CTGCAGCAAG TGACCTCGGG TCGTGGACCG CTGCCCTGCC CCCTCCGCTG CCACCTGGGG      60

CGGCGCGGGC CCGGTGCCCC GGATCGCGCG TAGAGCCGGC GCG ATG CAC GTG CGC      115
                                                Met His Val Arg
                                                  1

TCG CTG CGC GCT GCG GCG CCA CAC AGC TTC GTG GCG CTC TGG GCG CCT      163
Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala Leu Trp Ala Pro
  5                  10                  15                  20

CTG TTC TTG CTG CGC TCC GCC CTG GCC GAT TTC AGC CTG GAC AAC GAG      211
Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser Leu Asp Asn Glu
                  25                  30                  35

GTG CAC TCC AGC TTC ATC CAC CGG CGC CTC CGC AGC CAG GAG CGG CGG      259
Val His Ser Ser Phe Ile His Arg Arg Leu Arg Ser Gln Glu Arg Arg
             40                  45                  50

GAG ATG CAG CGG GAG ATC CTG TCC ATC TTA GGG TTG CCC CAT CGC CCG      307
Glu Met Gln Arg Glu Ile Leu Ser Ile Leu Gly Leu Pro His Arg Pro
         55                  60                  65

CGC CCG CAC CTC CAG GGA AAG CAT AAT TCG GCG CCC ATG TTC ATG TTG      355
Arg Pro His Leu Gln Gly Lys His Asn Ser Ala Pro Met Phe Met Leu
     70                  75                  80

GAC CTG TAC AAC GCC ATG GCG GTG GAG GAG AGC GGG CCG GAC GGA CAG      403
Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Ser Gly Pro Asp Gly Gln
 85                  90                  95                  100

GGC TTC TCC TAC CCC TAC AAG GCC GTC TTC AGT ACC CAG GGC CCC CCT      451
Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser Thr Gln Gly Pro Pro
                105                 110                 115

TTA GCC AGC CTG CAG GAC AGC CAT TTC CTC ACT GAC GCC GAC ATG GTC      499
Leu Ala Ser Leu Gln Asp Ser His Phe Leu Thr Asp Ala Asp Met Val
            120                 125                 130

ATG AGC TTC GTC AAC CTA GTG GAA CAT GAC AAA GAA TTC TTC CAC CCT      547
Met Ser Phe Val Asn Leu Val Glu His Asp Lys Glu Phe Phe His Pro
        135                 140                 145

CGA TAC CAC CAT CGG GAG TTC CGG TTT GAT CTT TCC AAG ATC CCC GAG      595
Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu Ser Lys Ile Pro Glu
    150                 155                 160

GGC GAA GCG GTG ACC GCA GCC GAA TTC AGG ATC TAT AAG GAC TAC ATC      643
Gly Glu Ala Val Thr Ala Ala Glu Phe Arg Ile Tyr Lys Asp Tyr Ile
165                 170                 175                 180
```

```
CGG GAG CGA TTT GAC AAC GAG ACC TTC CAG ATC ACA GTC TAT CAG TGG      691
Arg Glu Arg Phe Asp Asn Glu Thr Phe Gln Ile Thr Val Tyr Gln Trp
                185                 190                 195

CTC CAG GAG CAC TCA GGC AGG GAG TCG GAC CTC TTC TTG CTG GAC AGC      739
Leu Gln Glu His Ser Gly Arg Glu Ser Asp Leu Phe Leu Leu Asp Ser
            200                 205                 210

CGC ACC ATC TGG GCT TCT GAG GAG GGC TGG TTG GTG TTT GAT ATC ACA      787
Arg Thr Ile Trp Ala Ser Glu Glu Gly Trp Leu Val Phe Asp Ile Thr
        215                 220                 225

GCC ACC AGC AAC CAC TGG GTG GTC AAC CCT CGG CAC AAC CTG GGC TTA      835
Ala Thr Ser Asn His Trp Val Val Asn Pro Arg His Asn Leu Gly Leu
    230                 235                 240

CAG CTC TCT GTG GAG ACC CTG GAT GGG CAG AGC ATC AAC CCC AAG TTG      883
Gln Leu Ser Val Glu Thr Leu Asp Gly Gln Ser Ile Asn Pro Lys Leu
245                 250                 255                 260

GCA GGC CTG ATT GGA CGG CAT GGA CCC CAG AAC AAG CAA CCC TTC ATG      931
Ala Gly Leu Ile Gly Arg His Gly Pro Gln Asn Lys Gln Pro Phe Met
                265                 270                 275

GTG GCC TTC TTC AAG GCC ACG GAA GTC CAT CTC CGT AGT ATC CGG TCC      979
Val Ala Phe Phe Lys Ala Thr Glu Val His Leu Arg Ser Ile Arg Ser
            280                 285                 290

ACG GGG GGC AAG CAG CGC AGC CAG AAT CGC TCC AAG ACG CCA AAG AAC     1027
Thr Gly Gly Lys Gln Arg Ser Gln Asn Arg Ser Lys Thr Pro Lys Asn
        295                 300                 305

CAA GAG GCC CTG AGG ATG GCC AGT GTG GCA GAA AAC AGC AGC AGT GAC     1075
Gln Glu Ala Leu Arg Met Ala Ser Val Ala Glu Asn Ser Ser Ser Asp
    310                 315                 320

CAG AGG CAG GCC TGC AAG AAA CAT GAG CTG TAC GTC AGC TTC CGA GAC     1123
Gln Arg Gln Ala Cys Lys Lys His Glu Leu Tyr Val Ser Phe Arg Asp
325                 330                 335                 340

CTT GGC TGG CAG GAC TGG ATC ATT GCA CCT GAA GGC TAT GCT GCC TAC     1171
Leu Gly Trp Gln Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala Ala Tyr
                345                 350                 355

TAC TGT GAG GGA GAG TGC GCC TTC CCT CTG AAC TCC TAC ATG AAC GCC     1219
Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met Asn Ala
            360                 365                 370

ACC AAC CAC GCC ATC GTC CAG ACA CTG GTT CAC TTC ATC AAC CCA GAC     1267
Thr Asn His Ala Ile Val Gln Thr Leu Val His Phe Ile Asn Pro Asp
        375                 380                 385
```

```
ACA GTA CCC AAG CCC TGC TGT GCG CCC ACC CAG CTC AAC GCC ATC TCT      1315
Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gln Leu Asn Ala Ile Ser
    390                 395                 400

GTC CTC TAC TTC GAC GAC AGC TCT AAT GTC ATC CTG AAG AAG TAC AGA      1363
Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile Leu Lys Lys Tyr Arg
405                 410                 415                 420

AAC ATG GTG GTC CGG GCC TGT GGC TGC CAC TAGCTCTTCC TGAGACCCTG        1413
Asn Met Val Val Arg Ala Cys Gly Cys His
                425                 430

ACCTTTGCGG GGCCACACCT TTCCAAATCT TCGATGTCTC ACCATCTAAG TCTCTCACTG    1473

CCCACCTTGG CGAGGAGAAC AGACCAACCT CTCCTGAGCC TTCCCTCACC TCCCAACCGG    1533

AAGCATGTAA GGGTTCCAGA AACCTGAGCG TGCAGCAGCT GATGAGCGCC CTTTCCTTCT    1593

GGCACGTGAC GGACAAGATC CTACCAGCTA CCACAGCAAA CGCCTAAGAG CAGGAAAAAT    1653

GTCTGCCAGG AAAGTGTCCA GTGTCCACAT GGCCCCTGGC GCTCTGAGTC TTTGAGGAGT    1713

AATCGCAAGC CTCGTTCAGC TGCAGCAGAA GGAAGGGCTT AGCCAGGGTG GGCGCTGGCG    1773

TCTGTGTTGA AGGGAAACCA AGCAGAAGCC ACTGTAATGA TATGTCACAA TAAAACCCAT    1833

GAATGAAAAA AAAAAAAAAA AAAAAAAAAA AAAAGAATTC                          1873
```

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 430 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:
(D) OTHER INFORMATION: /product= "mOP1-PP"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

```
Met His Val Arg Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala
 1               5                  10                  15

Leu Trp Ala Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser
            20                  25                  30

Leu Asp Asn Glu Val His Ser Ser Phe Ile His Arg Arg Leu Arg Ser
        35                  40                  45
```

Gln Glu Arg Arg Glu Met Gln Arg Glu Ile Leu Ser Ile Leu Gly Leu
50 55 60

Pro His Arg Pro Arg Pro His Leu Gln Gly Lys His Asn Ser Ala Pro
65 70 75 80

Met Phe Met Leu Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Ser Gly
85 90 95

Pro Asp Gly Gln Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser Thr
100 105 110

Gln Gly Pro Pro Leu Ala Ser Leu Gln Asp Ser His Phe Leu Thr Asp
115 120 125

Ala Asp Met Val Met Ser Phe Val Asn Leu Val Glu His Asp Lys Glu
130 135 140

Phe Phe His Pro Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu Ser
145 150 155 160

Lys Ile Pro Glu Gly Glu Ala Val Thr Ala Ala Glu Phe Arg Ile Tyr
165 170 175

Lys Asp Tyr Ile Arg Glu Arg Phe Asp Asn Glu Thr Phe Gln Ile Thr
180 185 190

Val Tyr Gln Trp Leu Gln Glu His Ser Gly Arg Glu Ser Asp Leu Phe
195 200 205

Leu Leu Asp Ser Arg Thr Ile Trp Ala Ser Glu Glu Gly Trp Leu Val
210 215 220

Phe Asp Ile Thr Ala Thr Ser Asn His Trp Val Val Asn Pro Arg His
225 230 235 240

Asn Leu Gly Leu Gln Leu Ser Val Glu Thr Leu Asp Gly Gln Ser Ile
245 250 255

Asn Pro Lys Leu Ala Gly Leu Ile Gly Arg His Gly Pro Gln Asn Lys
260 265 270

Gln Pro Phe Met Val Ala Phe Phe Lys Ala Thr Glu Val His Leu Arg
275 280 285

Ser Ile Arg Ser Thr Gly Gly Lys Gln Arg Ser Gln Asn Arg Ser Lys
290 295 300

Thr Pro Lys Asn Gln Glu Ala Leu Arg Met Ala Ser Val Ala Glu Asn
305 310 315 320

Ser Ser Ser Asp Gln Arg Gln Ala Cys Lys Lys His Glu Leu Tyr Val
325 330 335

Ser Phe Arg Asp Leu Gly Trp Gln Asp Trp Ile Ile Ala Pro Glu Gly
340 345 350

Tyr Ala Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser
355 360 365

Tyr Met Asn Ala Thr Asn His Ala Ile Val Gln Thr Leu Val His Phe
370 375 380

Ile Asn Pro Asp Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gln Leu
385 390 395 400

Asn Ala Ile Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile Leu
405 410 415

Lys Lys Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His
420 425 430

(2) INFORMATION FOR SEQ ID NO:20:

(i)SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1723 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii)MOLECULE TYPE: cDNA

(vi)ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens
(F) TISSUE TYPE: HIPPOCAMPUS

(ix)FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 490..1696
(D) OTHER INFORMATION: /note= "hOP2 (cDNA)"

(xi)SEQUENCE DESCRIPTION: SEQ ID NO:20:

GGCGCCGGCA GAGCAGGAGT GGCTGGAGGA GCTGTGGTTG GAGCAGGAGG TGGCACGGCA 60

GGGCTGGAGG GCTCCCTATG AGTGGCGGAG ACGGCCCAGG AGGCGCTGGA GCAACAGCTC 120

CCACACCGCA CCAAGCGGTG GCTGCAGGAG CTCGCCCATC GCCCCTGCGC TGCTCGGACC 180

GCGGCCACAG CCGGACTGGC GGGTACGGCG GCGACAGAGG CATTGGCCGA GAGTCCCAGT 240

CCGCAGAGTA GCCCCGGCCT CGAGGCGGTG GCGTCCCGGT CCTCTCCGTC CAGGAGCCAG 300

GACAGGTGTC GCGCGGCGGG GCTCCAGGGA CCGCGCCTGA GGCCGGCTGC CCGCCCGTCC 360

CGCCCCGCCC CGCCGCCCGC CGCCCGCCGA GCCCAGCCTC CTTGCCGTCG GGGCGTCCCC 420

```
AGGCCCTGGG TCGGCCGCGG AGCCGATGCG CGCCCGCTGA GCGCCCCAGC TGAGCGCCCC      480

CGGCCTGCC ATG ACC GCG CTC CCC GGC CCG CTC TGG CTC CTG GGC CTG          528
          Met Thr Ala Leu Pro Gly Pro Leu Trp Leu Leu Gly Leu
            1               5                  10

GCG CTA TGC GCG CTG GGC GGG GGC GGC CCC GGC CTG CGA CCC CCG CCC        576
Ala Leu Cys Ala Leu Gly Gly Gly Gly Pro Gly Leu Arg Pro Pro Pro
     15                  20                  25

GGC TGT CCC CAG CGA CGT CTG GGC GCG CGC GAG CGC CGG GAC GTG CAG        624
Gly Cys Pro Gln Arg Arg Leu Gly Ala Arg Glu Arg Arg Asp Val Gln
 30                  35                  40                  45

CGC GAG ATC CTG GCG GTG CTC GGG CTG CCT GGG CGG CCC CGG CCC CGC        672
Arg Glu Ile Leu Ala Val Leu Gly Leu Pro Gly Arg Pro Arg Pro Arg
                 50                  55                  60

GCG CCA CCC GCC GCC TCC CGG CTG CCC GCG TCC GCG CCG CTC TTC ATG        720
Ala Pro Pro Ala Ala Ser Arg Leu Pro Ala Ser Ala Pro Leu Phe Met
            65                  70                  75

CTG GAC CTG TAC CAC GCC ATG GCC GGC GAC GAC GAC GAG GAC GGC GCG        768
Leu Asp Leu Tyr His Ala Met Ala Gly Asp Asp Asp Glu Asp Gly Ala
        80                  85                  90

CCC GCG GAG CGG CGC CTG GGC CGC GCC GAC CTG GTC ATG AGC TTC GTT        816
Pro Ala Glu Arg Arg Leu Gly Arg Ala Asp Leu Val Met Ser Phe Val
     95                  100                 105

AAC ATG GTG GAG CGA GAC CGT GCC CTG GGC CAC CAG GAG CCC CAT TGG        864
Asn Met Val Glu Arg Asp Arg Ala Leu Gly His Gln Glu Pro His Trp
110                 115                 120                 125

AAG GAG TTC CGC TTT GAC CTG ACC CAG ATC CCG GCT GGG GAG GCG GTC        912
Lys Glu Phe Arg Phe Asp Leu Thr Gln Ile Pro Ala Gly Glu Ala Val
                130                 135                 140

ACA GCT GCG GAG TTC CGG ATT TAC AAG GTG CCC AGC ATC CAC CTG CTC        960
Thr Ala Ala Glu Phe Arg Ile Tyr Lys Val Pro Ser Ile His Leu Leu
            145                 150                 155

AAC AGG ACC CTC CAC GTC AGC ATG TTC CAG GTG GTC CAG GAG CAG TCC       1008
Asn Arg Thr Leu His Val Ser Met Phe Gln Val Val Gln Glu Gln Ser
        160                 165                 170

AAC AGG GAG TCT GAC TTG TTC TTT TTG GAT CTT CAG ACG CTC CGA GCT       1056
Asn Arg Glu Ser Asp Leu Phe Phe Leu Asp Leu Gln Thr Leu Arg Ala
    175                 180                 185

GGA GAC GAG GGC TGG CTG GTG CTG GAT GTC ACA GCA GCC AGT GAC TGC       1104
Gly Asp Glu Gly Trp Leu Val Leu Asp Val Thr Ala Ala Ser Asp Cys
190                 195                 200                 205
```

```
TGG TTG CTG AAG CGT CAC AAG GAC CTG GGA CTC CGC CTC TAT GTG GAG      1152
Trp Leu Leu Lys Arg His Lys Asp Leu Gly Leu Arg Leu Tyr Val Glu
                210                 215                 220

ACT GAG GAC GGG CAC AGC GTG GAT CCT GGC CTG GCC GGC CTG CTG GGT      1200
Thr Glu Asp Gly His Ser Val Asp Pro Gly Leu Ala Gly Leu Leu Gly
            225                 230                 235

CAA CGG GCC CCA CGC TCC CAA CAG CCT TTC GTG GTC ACT TTC TTC AGG      1248
Gln Arg Ala Pro Arg Ser Gln Gln Pro Phe Val Val Thr Phe Phe Arg
        240                 245                 250

GCC AGT CCG AGT CCC ATC CGC ACC CCT CGG GCA GTG AGG CCA CTG AGG      1296
Ala Ser Pro Ser Pro Ile Arg Thr Pro Arg Ala Val Arg Pro Leu Arg
    255                 260                 265

AGG AGG CAG CCG AAG AAA AGC AAC GAG CTG CCG CAG GCC AAC CGA CTC      1344
Arg Arg Gln Pro Lys Lys Ser Asn Glu Leu Pro Gln Ala Asn Arg Leu
270                 275                 280                 285

CCA GGG ATC TTT GAT GAC GTC CAC GGC TCC CAC GGC CGG CAG GTC TGC      1392
Pro Gly Ile Phe Asp Asp Val His Gly Ser His Gly Arg Gln Val Cys
                290                 295                 300

CGT CGG CAC GAG CTC TAC GTC AGC TTC CAG GAC CTC GGC TGG CTG GAC      1440
Arg Arg His Glu Leu Tyr Val Ser Phe Gln Asp Leu Gly Trp Leu Asp
            305                 310                 315

TGG GTC ATC GCT CCC CAA GGC TAC TCG GCC TAT TAC TGT GAG GGG GAG      1488
Trp Val Ile Ala Pro Gln Gly Tyr Ser Ala Tyr Tyr Cys Glu Gly Glu
        320                 325                 330

TGC TCC TTC CCA CTG GAC TCC TGC ATG AAT GCC ACC AAC CAC GCC ATC      1536
Cys Ser Phe Pro Leu Asp Ser Cys Met Asn Ala Thr Asn His Ala Ile
    335                 340                 345

CTG CAG TCC CTG GTG CAC CTG ATG AAG CCA AAC GCA GTC CCC AAG GCG      1584
Leu Gln Ser Leu Val His Leu Met Lys Pro Asn Ala Val Pro Lys Ala
350                 355                 360                 365

TGC TGT GCA CCC ACC AAG CTG AGC GCC ACC TCT GTG CTC TAC TAT GAC      1632
Cys Cys Ala Pro Thr Lys Leu Ser Ala Thr Ser Val Leu Tyr Tyr Asp
                370                 375                 380

AGC AGC AAC AAC GTC ATC CTG CGC AAA CAC CGC AAC ATG GTG GTC AAG      1680
Ser Ser Asn Asn Val Ile Leu Arg Lys His Arg Asn Met Val Val Lys
            385                 390                 395

GCC TGC GGC TGC CAC T GAGTCAGCCC GCCCAGCCCT ACTGCAG                  1723
Ala Cys Gly Cys His
        400
```

(2) INFORMATION FOR SEQ ID NO:21:

(i)SEQUENCE CHARACTERISTICS:
(A) LENGTH: 402 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii)MOLECULE TYPE: protein

(ix)FEATURE:
(A)OTHER INFORMATION: /product= "hOP2-PP"

(xi)SEQUENCE DESCRIPTION: SEQ ID NO:21:

Met Thr Ala Leu Pro Gly Pro Leu Trp Leu Leu Gly Leu Ala Leu Cys
1 5 10 15

Ala Leu Gly Gly Gly Gly Pro Gly Leu Arg Pro Pro Pro Gly Cys Pro
20 25 30

Gln Arg Arg Leu Gly Ala Arg Glu Arg Arg Asp Val Gln Arg Glu Ile
35 40 45

Leu Ala Val Leu Gly Leu Pro Gly Arg Pro Arg Pro Arg Ala Pro Pro
50 55 60

Ala Ala Ser Arg Leu Pro Ala Ser Ala Pro Leu Phe Met Leu Asp Leu
65 70 75 80

Tyr His Ala Met Ala Gly Asp Asp Asp Glu Asp Gly Ala Pro Ala Glu
85 90 95

Arg Arg Leu Gly Arg Ala Asp Leu Val Met Ser Phe Val Asn Met Val
100 105 110

Glu Arg Asp Arg Ala Leu Gly His Gln Glu Pro His Trp Lys Glu Phe
115 120 125

Arg Phe Asp Leu Thr Gln Ile Pro Ala Gly Glu Ala Val Thr Ala Ala
130 135 140

Glu Phe Arg Ile Tyr Lys Val Pro Ser Ile His Leu Leu Asn Arg Thr
145 150 155 160

Leu His Val Ser Met Phe Gln Val Val Gln Glu Gln Ser Asn Arg Glu
165 170 175

Ser Asp Leu Phe Phe Leu Asp Leu Gln Thr Leu Arg Ala Gly Asp Glu
180 185 190

Gly Trp Leu Val Leu Asp Val Thr Ala Ala Ser Asp Cys Trp Leu Leu
195 200 205

Lys Arg His Lys Asp Leu Gly Leu Arg Leu Tyr Val Glu Thr Glu Asp
210 215 220

Gly His Ser Val Asp Pro Gly Leu Ala Gly Leu Leu Gly Gln Arg Ala
225 230 235 240

Pro Arg Ser Gln Gln Pro Phe Val Val Thr Phe Phe Arg Ala Ser Pro
245 250 255

Ser Pro Ile Arg Thr Pro Arg Ala Val Arg Pro Leu Arg Arg Arg Gln
260 265 270

Pro Lys Lys Ser Asn Glu Leu Pro Gln Ala Asn Arg Leu Pro Gly Ile
275 280 285

Phe Asp Asp Val His Gly Ser His Gly Arg Gln Val Cys Arg Arg His
290 295 300

Glu Leu Tyr Val Ser Phe Gln Asp Leu Gly Trp Leu Asp Trp Val Ile
305 310 315 320

Ala Pro Gln Gly Tyr Ser Ala Tyr Tyr Cys Glu Gly Glu Cys Ser Phe
325 330 335

Pro Leu Asp Ser Cys Met Asn Ala Thr Asn His Ala Ile Leu Gln Ser
340 345 350

Leu Val His Leu Met Lys Pro Asn Ala Val Pro Lys Ala Cys Cys Ala
355 360 365

Pro Thr Lys Leu Ser Ala Thr Ser Val Leu Tyr Tyr Asp Ser Ser Asn
370 375 380

Asn Val Ile Leu Arg Lys His Arg Asn Met Val Val Lys Ala Cys Gly
385 390 395 400

Cys His

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1926 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:
(A) ORGANISM: MURIDAE
(F) TISSUE TYPE: EMBRYO

(ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: 93..1289
(D) OTHER INFORMATION: /note= "mOP2 cDNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

```
GCCAGGCACA GGTGCGCCGT CTGGTCCTCC CCGTCTGGCG TCAGCCGAGC                  50

CCGACCAGCT ACCAGTGGAT GCGCGCCGGC TGAAAGTCCG AG ATG GCT ATG CGT          104
                                                  Met Ala Met Arg
                                                    1

CCC GGG CCA CTC TGG CTA TTG GGC CTT GCT CTG TGC GCG CTG GGA GGC         152
Pro Gly Pro Leu Trp Leu Leu Gly Leu Ala Leu Cys Ala Leu Gly Gly
  5                  10                  15                  20

GGC CAC GGT CCG CGT CCC CCG CAC ACC TGT CCC CAG CGT CGC CTG GGA         200
Gly His Gly Pro Arg Pro Pro His Thr Cys Pro Gln Arg Arg Leu Gly
                  25                  30                  35

GCG CGC GAG CGC CGC GAC ATG CAG CGT GAA ATC CTG GCG GTG CTC GGG         248
Ala Arg Glu Arg Arg Asp Met Gln Arg Glu Ile Leu Pro Val Leu Gly
             40                  45                  50

CTA CCG GGA CGG CCC CGA CCC CGT GCA CAA CCC GCG GCT GCC CGG CAG         296
Leu Pro Gly Arg Pro Arg Pro Arg Ala Gln Pro Ala Ala Ala Arg Gln
         55                  60                  65

CCA GCG TCC GCG CCC CTC TTC ATG TTG GAC CTA TAC CAC GCC ATG ACC         344
Pro Ala Ser Ala Pro Leu Phe Met Leu Asp Leu Tyr His Ala Met Thr
     70                  75                  80

GAT GAC GAC GAC GGC GGG CCA CCA CAG GCT CAC TTA GGC CGT GCC GAC         392
Asp Asp Asp Asp Gly Gly Pro Pro Gln Ala His Leu Gly Arg Ala Asp
 85                  90                  95                 100

CTG GTC ATG AGC TTC GTC AAC ATG GTG GAA CGC GAC CGT ACC CTG GGC         440
Leu Val Met Ser Phe Val Asn Met Val Glu Arg Asp Arg Thr Leu Gly
                105                 110                 115

TAC CAG GAG CCA CAC TGG AAG GAA TTC CAC TTT GAC CTA ACC CAG ATC         488
Tyr Gln Glu Pro His Trp Lys Glu Phe His Phe Asp Leu Thr Gln Ile
            120                 125                 130

CCT GCT GGG GAG GCT GTC ACA GCT GCT GAG TTC CGG ATC TAC AAA GAA         536
Pro Ala Gly Glu Ala Val Thr Ala Ala Glu Phe Arg Ile Tyr Lys Glu
        135                 140                 145

CCC AGC ACC CAC CCG CTC AAC ACA ACC CTC CAC ATC AGC ATG TTC GAA         584
Pro Ser Thr His Pro Leu Asn Thr Thr Leu His Ile Ser Met Phe Glu
    150                 155                 160
```

```
GTG GTC CAA GAG CAC TCC AAC AGG GAG TCT GAC TTG TTC TTT TTG GAT      632
Val Val Gln Glu His Ser Asn Arg Glu Ser Asp Leu Phe Phe Leu Asp
165                 170                 175                 180

CTT CAG ACG CTC CGA TCT GGG GAC GAG GGC TGG CTG GTG CTG GAC ATC      680
Leu Gln Thr Leu Arg Ser Gly Asp Glu Gly Trp Leu Val Leu Asp Ile
                185                 190                 195

ACA GCA GCC AGT GAC CGA TGG CTG CTG AAC CAT CAC AAG GAC CTG GGA      728
Thr Ala Ala Ser Asp Arg Trp Leu Leu Asn His His Lys Asp Leu Gly
            200                 205                 210

CTC CGC CTC TAT GTG GAA ACC GCG GAT GGG CAC AGC ATG GAT CCT GGC      776
Leu Arg Leu Tyr Val Glu Thr Ala Asp Gly His Ser Met Asp Pro Gly
        215                 220                 225

CTG GCT GGT CTG CTT GGA CGA CAA GCA CCA CGC TCC AGA CAG CCT TTC      824
Leu Ala Gly Leu Leu Gly Arg Gln Ala Pro Arg Ser Arg Gln Pro Phe
    230                 235                 240

ATG GTA ACC TTC TTC AGG GCC AGC CAG AGT CCT GTG CGG GCC CCT CGG      872
Met Val Thr Phe Phe Arg Ala Ser Gln Ser Pro Val Arg Ala Pro Arg
245                 250                 255                 260

GCA GCG AGA CCA CTG AAG AGG AGG CAG CCA AAG AAA ACG AAC GAG CTT      920
Ala Ala Arg Pro Leu Lys Arg Arg Gln Pro Lys Lys Thr Asn Glu Leu
                265                 270                 275

CCG CAC CCC AAC AAA CTC CCA GGG ATC TTT GAT GAT GGC CAC GGT TCC      968
Pro His Pro Asn Lys Leu Pro Gly Ile Phe Asp Asp Gly His Gly Ser
            280                 285                 290

CGC GGC AGA GAG GTT TGC CGC AGG CAT GAG CTC TAC GTC AGC TTC CGT     1016
Arg Gly Arg Glu Val Cys Arg Arg His Glu Leu Tyr Val Ser Phe Arg
        295                 300                 305

GAC CTT GGC TGG CTG GAC TGG GTC ATC GCC CCC CAG GGC TAC TCT GCC     1064
Asp Leu Gly Trp Leu Asp Trp Val Ile Ala Pro Gln Gly Tyr Ser Ala
    310                 315                 320

TAT TAC TGT GAG GGG GAG TGT GCT TTC CCA CTG GAC TCC TGT ATG AAC     1112
Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asp Ser Cys Met Asn
325                 330                 335                 340

GCC ACC AAC CAT GCC ATC TTG CAG TCT CTG GTG CAC CTG ATG AAG CCA     1160
Ala Thr Asn His Ala Ile Leu Gln Ser Leu Val His Leu Met Lys Pro
                345                 350                 355

GAT GTT GTC CCC AAG GCA TGC TGT GCA CCC ACC AAA CTG AGT GCC ACC     1208
Asp Val Val Pro Lys Ala Cys Cys Ala Pro Thr Lys Leu Ser Ala Thr
            360                 365                 370
```

```
TCT GTG CTG TAC TAT GAC AGC AGC AAC AAT GTC ATC CTG CGT AAA CAC      1256
Ser Val Leu Tyr Tyr Asp Ser Ser Asn Asn Val Ile Leu Arg Lys His
        375                 380                 385

CGT AAC ATG GTG GTC AAG GCC TGT GGC TGC CAC TGAGGCCCCG CCCAGCATCC    1309
Arg Asn Met Val Val Lys Ala Cys Gly Cys His
    390                 395

TGCTTCTACT ACCTTACCAT CTGGCCGGGC CCCTCTCCAG AGGCAGAAAC CCTTCTATGT    1369

TATCATAGCT CAGACAGGGG CAATGGGAGG CCCTTCACTT CCCCTGGCCA CTTCCTGCTA    1429

AAATTCTGGT CTTTCCCAGT TCCTCTGTCC TTCATGGGGT TTCGGGGCTA TCACCCCGCC    1489

CTCTCCATCC TCCTACCCCA AGCATAGACT GAATGCACAC AGCATCCCAG AGCTATGCTA    1549

ACTGAGAGGT CTGGGGTCAG CACTGAAGGC CCACATGAGG AAGACTGATC CTTGGCCATC    1609

CTCAGCCCAC AATGGCAAAT TCTGGATGGT CTAAGAAGGC CGTGGAATTC TAAACTAGAT    1669

GATCTGGGCT CTCTGCACCA TTCATTGTGG CAGTTGGGAC ATTTTTAGGT ATAACAGACA    1729

CATACACTTA GATCAATGCA TCGCTGTACT CCTTGAAATC AGAGCTAGCT TGTTAGAAAA    1789

AGAATCAGAG CCAGGTATAG CGGTGCATGT CATTAATCCC AGCGCTAAAG AGACAGAGAC    1849

AGGAGAATCT CTGTGAGTTC AAGGCCACAT AGAAAGAGCC TGTCTCGGGA GCAGGAAAAA    1909

AAAAAAAAAC GGAATTC                                                   1926
```

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 399 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:
(D) OTHER INFORMATION: /product= "mOP2-PP"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

```
Met Ala Met Arg Pro Gly Pro Leu Trp Leu Leu Gly Leu Ala Leu Cys
 1               5                  10                  15

Ala Leu Gly Gly Gly His Gly Pro Arg Pro Pro His Thr Cys Pro Gln
            20                  25                  30

Arg Arg Leu Gly Ala Arg Glu Arg Arg Asp Met Gln Arg Glu Ile Leu Ala
        35                  40                  45
```

```
Val Leu Gly Leu Pro Gly Arg Pro Arg Pro Arg Ala Gln Pro Ala Ala
 50                  55                  60                  65

Ala Arg Gln Pro Ala Ser Ala Pro Leu Phe Met Leu Asp Leu Tyr His Ala
                 70                  75                  80

Met Thr Asp Asp Asp Asp Gly Gly Pro Pro Gln Ala His Leu Gly Arg
         85                  90                  95

Ala Asp Leu Val Met Ser Phe Val Asn Met Val Glu Arg Asp Arg Thr
    100                 105                 110

Leu Gly Tyr Gln Glu Pro His Trp Lys Glu Phe His Phe Asp Leu Thr
115                 120                 125                 130

Gln Ile Pro Ala Gly Glu Ala Val Thr Ala Ala Glu Phe Arg Ile Tyr
                135                 140                 145

Lys Glu Pro Ser Thr His Pro Leu Asn Thr Thr Leu His Ile Ser Met
            150                 155                 160

Phe Glu Val Val Gln Glu His Ser Asn Arg Glu Ser Asp Leu Phe Phe
        165                 170                 175

Leu Asp Leu Gln Thr Leu Arg Ser Gly Asp Glu Gly Trp Leu Val Leu
    180                 185                 190

Asp Ile Thr Ala Ala Ser Asp Arg Trp Leu Leu Asn His His Lys Asp
195                 200                 205                 210

Leu Gly Leu Arg Leu Tyr Val Glu Thr Ala Asp Gly His Ser Met Asp
                215                 220                 225

Pro Gly Leu Ala Gly Leu Leu Gly Arg Gln Ala Pro Arg Ser Arg Gln
            230                 235                 240

Pro Phe Met Val Thr Phe Phe Arg Ala Ser Gln Ser Pro Val Arg Ala
        245                 250                 255

Pro Arg Ala Ala Arg Pro Leu Lys Arg Arg Gln Pro Lys Lys Thr Asn
    260                 265                 270

Glu Leu Pro His Pro Asn Lys Leu Pro Gly Ile Phe Asp Asp Gly His
275                 280                 285                 290

Gly Ser Arg Gly Arg Glu Val Cys Arg Arg His Glu Leu Tyr Val Ser
                295                 300                 305

Phe Arg Asp Leu Gly Trp Leu Asp Trp Val Ile Ala Pro Gln Gly Tyr
            310                 315                 320
```

```
Ser Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asp Ser Cys
        325                 330                 335

Met Asn Ala Thr Asn His Ala Ile Leu Gln Ser Leu Val His Leu Met
    340                 345                 350

Lys Pro Asp Val Val Pro Lys Ala Cys Cys Ala Pro Thr Lys Leu Ser
355                 360                 365                 370

Ala Thr Ser Val Leu Tyr Tyr Asp Ser Ser Asn Asn Val Ile Leu Arg
                375                 380                 385

Lys His Arg Asn Met Val Val Lys Ala Cys Gly Cys His
            390                 395
```

What is claimed is:

1. A composition for increasing the progenitor cell population in a mammal comprising:

progenitor cells, stimulated ex vivo by exposure to a morphogen at a concentration and for a time sufficient such that said progenitor cells are stimulated to proliferate.

2. A composition for inducing non-chondrogenic tissue growth in a mammal comprising:

progenitor cells, stimulated by exposure to a morphogen at a concentration and for a time sufficient such that said progenitor cells, when disposed in vivo within a tissue locus, are capable of non-chondrogenic tissue-specific differentiation and proliferation within said locus.

3. The composition of claim 1 or 2 wherein said progenitor cells are hemopoietic pluripotential stem cells.

4. The composition of claim 1 or 2 wherein said progenitor cells are of mesenchymal origin.

5. A composition for inducing the formation of non-chondrogenic replacement tissue at a tissue locus in a mammal comprising:

a biocompatible, acellular matrix having components specific for said tissue and capable of providing a morphogenically permissive, tissue-specific environment; and

a morphogen such that said morphogen, when absorbed on said matrix and provided to a

tissue-specific locus requiring replacement tissue, is capable of inducing the d velopmental cascade of tissue morphogenesis at said locus.

6. A composition for inducing the formation of non-chondrogenic replacement tissue at a tissue locus in a mammal comprising:

a biocompatible, acellular matrix capable of providing a morphogenically permissive environment; and

a morphogen such that said morphogen, when absorbed on said matrix and provided to a tissue-specific locus requiring replacement tissue, is capable of inducing the developmental cascade of tissue morphogenesis at said locus.

7. The composition of claim 5 or 6 wherein said matrix is biodegradable.

8. The composition of claim 5 or 6 wherein said matrix is derived from organ-specific tissue.

9. The composition of claim 5 or 6 wherein said matrix comprises collagen and cell attachment factors selected from the group consisting of glycosaminoglycans and proteoglycans.

10. The composition of claim 5 or 6 wherein said matrix defines pores of a dimension sufficient to permit the influx, differentiation and proliferation of migratory progenitor cells from the body of said mammal.

11. The composition of claim 1, 2, 5 or 6 wherein said morphogen comprises an amino acid s quence sharing at least 70% homology with ne of the sequences selected from the group consisting of: hOP1 (Seq. ID No. 5); mOP1 (Seq. ID No. 6); hOP2 (Seq. ID No. 7); mOP2 (Seq. ID No. 8); CBMP2A(fx) (Seq. ID No. 9); CBMP2B(fx) (Seq. ID No. 10); DPP(fx) (Seq. ID No. 11); Vgl(fx) (Seq. ID No. 12); Vgr-1(fx) (Seq. ID No. 13); and GDF-1(fx) (Seq. ID No. 14).

12. The composition of claim 11 wherein said morphogen comprises an amino acid sequence sharing at least 80% homology with one of the sequences selected from said group.

13. The composition of claim 12 wherein said morphogen conprises an amino acid sequence having greater than 60% amino acid identity with the sequence defined by residues 43-139 of Seq. ID No.5 (hOP1).

14. The composition of claim 13 wherein said morphogen comprises an amino acid sequence having greater than 65% identity with the sequence defined by residues 43-139 of Seq. ID No.5 (hOP1).

15. A method of increasing a population of progenitor cells comprising the step of:

contacting progenitor cells with a morphogen at a concentration and for a time sufficient such that said progenitor cells are stimulated to proliferate.

16. The method of claim 15 for incr asing pr genit r cells in a mammal comprising the additional step of supplying said stimulated progenitor cells to a mammal to increase the progenitor cell population in said mammal.

17. A method of inducing non-chondrogenic tissue growth in a mammal comprising the step of:

contacting progenitor cells with a morphogen at a concentration and for a time sufficient such that said progenitor cells, when provided to a tissue-specific locus in a mammal, are capable of nonchondrogenic tissue-specific differentiation and proliferation at said locus.

18. The method of claim 14 or 16 wherein said progenitor cells are of mesenchymal origin.

19. A method of maintaining the phenotypic expression of differentiated cells in a mammal comprising the steps of:

contacting said differentiated cells with a morphogen at a concentration and for a time sufficient such that said cells are stimulated to express their phenotype.

20. The method of claim 19 wherein said differentiated cells are senescent or quiescent cells.

21. A method of inducing non-chondrogenic tissue growth at a tissue locus in a mammal comprising:

providing said locus with a morph gen at a conc ntration and for a time sufficient such that said protein, when provided to a m rphogenically permissive tissue-specific locus, is capable of inducing the developmental cascade of tissue morphogenesis at said locus.

22. The method of claim 21 wherein said nonchondrogenic tissue is hepatic tissue, and said tissue locus is the liver.

23. The method of claim 22 wherein said protein is provided to said locus in association with a biocompatible, acellular matrix.

24. The method of claim 23 wherein said matrix has components specific for said tissue.

25. The method of claim 23 wherein said matrix is biodegradable.

26. The method of claim 23 wherein said matrix is derived from organ-specific tissue.

27. The method of claim 23 wherein said matrix comprises collagen and cell attachment factors specific for said tissue.

28. The method of claim 23 wherein said matrix defines pores of a dimension sufficient to permit the influx, differentiation and proliferation of migratory progenitor cells from the body of said mammal.

29. The method of claim 14, 16, 17 or 20 where said morphogen comprises an amino acid sequence sharing at least 70% homology with one of the sequences selected from the group consisting of hOP1 (Seq. ID No. 5); mOP1 (Seq. ID No. 6); hOP2 (Seq. ID No. 7); mOP2 (Seq. ID No. 8); CBMP2A(fx) (Seq. ID No. 9); CBMP2B(fx) (Seq. ID No. 10); DPP(fx) (Seq. ID No. 11); Vgl(fx) (Seq. ID No. 12); Vgr-1(fx) (Seq. ID No. 13); and GDF-1(fx) (Seq. ID No. 14).

30. A method for inducing hepatic tissue formation at a damaged tissue locus in a mammalian liver comprising providing to said locus a therapeutic amount of a morphogen comprising at least residues 43-139 of hOP-1 (Seq. ID No. 5).

31. A method for diagnosing tissue dysfunction in a human, the method comprising the steps of :

(a) repeating, at intervals, the step of detecting the concentration of endogenous anti-morphogen antibody present in a human; and

(b) comparing said detected concentrations, wherein changes in the detected concentrations are indicative of status of said tissue.

32. A method for evaluating the status of a tissue, the method comprising the step of detecting the concentration of a morphogen present in said tissue.

33. The method of claim 32 comprising the additional steps of:

(a) repeating, at intervals, the step of detecting the concentration of morphogen present in said tissue; and

(b) comparing said detected concentrations, wherein changes in said detected concentrations are indicative of the status of said tissue.

34. The method of claim 33 wherein said morphogen is selected from the group consisting of: hOP1 (Seq. ID No. 5); mOP1 (Seq. ID No. 6); hOP2 (Seq. ID No. 7); mOP2 (Seq. ID No. 8); CBMP2A(fx) (Seq. ID No. 9); CBMP2B(fx) (Seq. ID No. 10); DPP(fx) (Seq. ID No. 11); Vgl(fx) (Seq. ID No. 12); Vgr-1(fx) (Seq. ID No. 13); and GDF-1(fx) (Seq. ID No. 14).

35. A morphogen useful in the manufacture of a pharmaceutical for use in the induction of non-chondrogenic mammalian tissue growth.

36. A morphogen useful in the manufacture of a pharmaceutical for use as an inducer of progenitor cell proliferation.

37. A morphogen useful in the manufacture of a pharmaceutical for use in maintaining the phenotypic expression of differentiated cells in a mammal.

38. A morphogen useful in the manufacture of a pharmaceutical for use in the induction of hepatic tissue growth.

39. The morphogen of claims 35, 36, 37, or 38 wherein said morphogen comprises an amino acid sequence sharing at least 70% homology with a sequence selected from the group consisting of: hOP1 (Seq. ID No. 5); mOP1 (Seq. ID No. 6); hOP2 (Seq. ID

No. 7); mOP2 (Seq. ID No. 8); CBMP2A(fx) (Seq. ID N . 9); CBMP2B(fx) (Seq. ID No. 10); DPP(fx) (Seq. ID No. 11); Vgl(fx) (Seq. ID No. 12); Vgr-1(fx) (Seq. ID No. 13); and GDF-1(fx) (Seq. ID No. 14).

40. The morphogen of Claim 39 wherein said morphogen comprises an amino acid sequence sharing at least 80% homology with one of the sequences selected from said group.

41. A morphogen useful in the manufacture of a pharmaceutical to inhibit neoplastic cell growth.

42. A cancer therapeutic agent comprising a morphogen.

43. A therapeutic agent for tissue growth induction, the therapeutic agent comprising a morphogen.

44. A therapeutic agent for inducing phenotypic expression of differentiated cells, the therapeutic agent comprising a morphogen.

45. A therapeutic agent for inducing progenitor cell proliferation, the therapeutic agent comprising a morphogen.




Fig. 1




Fig. 2


BRAIN,1
SPLEEN,2
LUNG,3
KIDNEY/ADRENAL,4
HEART,5
LIVER,6
ADRENAL,7
KIDNEY,8
KIDNEY/ADRENAL,9
HEART,10
9.49
7.46
4.40
2.37
1.35
1.8
A
B

Fig. 3



Fig. 4A



Fig. 4B



Fig. 5A



Fig. 5B



Fig. 6A



Fig. 6B



Fig. 6C



Fig. 6D

Fig. 7



Fig. 8A



Fig. 8B



Fig. 8C

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US92/01968

## I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)[3]

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC (5): A61K 37/12; A61F 2/02; C07K 13/00
US CL : 350/356, 402; 424/423, 426; 435/240.243

## II. FIELDS SEARCHED

Minimum Documentation Searched[4]

| Classification System | Classification Symbols |
|---|---|
| U.S. | 350/356, 402; 424/423, 426; 435/240.243 |

Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched[5]

CHEMICAL ABSTRACTS, APS

## III. DOCUMENTS CONSIDERED TO BE RELEVANT[14]

| Category* | Citation of Document,[16] with indication, where appropriate, of the relevant passages[17] | Relevant to Claim No.[18] |
|---|---|---|
| X/Y | WO, A, 89/09788 (OPPERMANN ET AL.) 19 OCTOBER 1989, see entire document. | 1/5-45 |
| X/Y | WO, A, 89/09787 (KUBERASAMPATH ET AL.) 19 OCTOBER 1989, see entire document. | 1/5-45 |

* Special categories of cited documents:[15]

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

## IV. CERTIFICATION

| Date of the Actual Completion of the International Search[2] | Date of Mailing of this International Search Report[2] |
|---|---|
| 12 June 1992 | 23 JUN 1992 |
| International Searching Authority[1] | Signature of Authorized Officer[20] |
| ISA/US | JAMES KETTER |